| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | RNA-Based Therapies | Oncology | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | RNA-Based Therapies | Oncology | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | RNA-Based Therapies | Oncology |
Recent Updates
Recently added Catalysts
AIM ImmunoTech Inc.$0.28
-0.01 (-2.38%)
C 45Pipeline Score Undervalued Biotech · Clinical
Market Cap
3.45 M
EPS
-7.30
P/E Ratio
-
Value Trade
6.15 M
SEC Financials
Q1 2026Dilution Risk
Revenue
22.00 K
R&D Expenses
482.00 K
Operating CF
-2.72 M
Total Assets
8.59 M
Total Liabilities
6.46 M
Equity
2.13 M
D/E Ratio
12,345
-8.77 %
Week
-52.56 %
1 Month
-78.63 %
3 Month
-81.59 %
6 Month
-99.89 %
5 Year
-100 %
All Time
Cash Data
Cash Position
5.88 M
Monthly Burn
906.00 K
Runway
4.9 mo
Burn Trend
StableSEC Filing
May 15, 2026
Overview
Volume
279.48 K
52 Week Range
0.21 - 20.33
% held by Insiders
72.25 %
% held by Institutions
0.63 %
Enterprise Value
2.15 M
Total Shares
8.15 M
Short %
28.11 %
Float Shares
7.83 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for AIM ImmunoTech Inc.
566Total events
10Upcoming
108Tier-1 (high impact)
2015 – 2039Coverage
Upcoming catalysts 10
Aug 2026
T3Last Patient Last Visit
Ampligen dosing completion for all subjects expected in August 2026
Jan 2027
T2Secondary Endpoint Data
Collection of additional secondary endpoint data expected to complete
Jun 2027
T2Secondary Endpoint Data
PFS, OS and other secondary endpoint assessments expected to begin in June 2027
Aug 9, 2039
T2Patent Granted
U.S. patent for Ampligen combination oncology therapy with anti-PD-L1 antibody expires August 9, 2039
Event history 556
Jul 7, 2026
▲Enrollment CompleteAmpligenTrial
Successful completion of patient enrollment and dosing in DURIPANC study
pancreatic cancersource ↗
Jul 7, 2026
Jul 7, 2026
▲Safety Data UpdateAmpligenClinical Data
Continued favorable safety findings
pancreatic cancersource ↗
Jul 7, 2026
▲Partnership / LicenseAmpligenCorporate
Strategic collaboration with AstraZeneca and Erasmus Medical Center
pancreatic cancersource ↗
Jun 24, 2026
◆Oral PresentationPresentation
AIM ImmunoTech to present in Webull Corporate Connect Webinar Series
Jun 24, 2026
▲Enrollment CompleteAmpligenTrial
Completed Phase 2 DURIPANC enrollment ahead of schedule
metastatic pancreatic cancersource ↗
Jun 24, 2026
▲Last Patient Last VisitAmpligenTrial
Dosed the final patient in the DURIPANC study
metastatic pancreatic cancersource ↗
Jun 24, 2026
▲Interim AnalysisAmpligenTrial
Reported positive interim clinical updates from DURIPANC
metastatic pancreatic cancersource ↗
Jun 24, 2026
▲Patent GrantedAmpligenIP / Competition
Expanded and strengthened global IP protection surrounding Ampligen and checkpoint inhibitor combinations
Jun 24, 2026
▲Orphan Drug DesignationAmpligenDesignation
Maintained orphan drug designation for pancreatic cancer in major markets
pancreatic cancersource ↗
Jun 24, 2026
Jun 18, 2026
▲First Patient DosedAmpligenTrial
Final subject received first dose in Phase 2 DURIPANC study
metastatic pancreatic cancersource ↗
Drug Pipeline Intelligence
C45
Pipeline Score $19M
Pipeline ValueUndervalued
Valuation Signal8
Drugs Scored5.3x
rNPV / MCap Top 67%
Micro Cap (rank 302 of 911)
Percentile RankAIM ImmunoTech Inc. carries a moderate pipeline score (45/100), with $3.0B risk-adjusted pipeline value, led by poly I-poly C12U in HIV Seropositivity (Phase 2), across $113B in total addressable markets, but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| poly I-poly C12U Small molecule | HIV Seropositivity | Phase 2 | NCT00035893 | 21% | $1.3B | COMPLETED | 40 | - | - | Aug 1, 2006 | - | Apr 17, 2013 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Ampligen Orphan | metastatic pancreatic cancer | Phase 2 | 2026-06-18 | Progression-Free Survival of 17.7 months compared to 8.6 months for historical controls, for an improvement of 9.1 months in PFS; Overall Survival of 34.8 months compared to 12.5 months for historical controls, for an improvement of 22.3 months in OS; Progression-Free Survival of 13.1 months compared to 8.6 months for historical controls, for an improvement of 4.5 months in PFS; Overall Survival of 24.1 months compared to 12.5 months for historical controls, for an improvement of 11.6 months in OS Read More | AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer Read More | |
Ampligen Orphan | metastatic pancreatic cancer | Phase 2 | 2026-06-18 | Progression-Free Survival of 17.7 months compared to 8.6 months for historical controls, for an improvement of 9.1 months in PFS; Overall Survival of 34.8 months compared to 12.5 months for historical controls, for an improvement of 22.3 months in OS; Progression-Free Survival of 13.1 months compared to 8.6 months for historical controls, for an improvement of 4.5 months in PFS; Overall Survival of 24.1 months compared to 12.5 months for historical controls, for an improvement of 11.6 months in OS Read More | AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer Read More | |
Ampligen Orphan | metastatic pancreatic cancer | Phase 2 | 2026-06-18 | Progression-Free Survival of 17.7 months compared to 8.6 months for historical controls, for an improvement of 9.1 months in PFS; Overall Survival of 34.8 months compared to 12.5 months for historical controls, for an improvement of 22.3 months in OS; Progression-Free Survival of 13.1 months compared to 8.6 months for historical controls, for an improvement of 4.5 months in PFS; Overall Survival of 24.1 months compared to 12.5 months for historical controls, for an improvement of 11.6 months in OS Read More | AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AIM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AIM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AIM▼ -2.4%today
AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program
AIM ImmunoTech announced the release of a CEO Corner segment highlighting the company's advancements in its pancreatic cancer program. CEO Thomas Equels discussed the successful completion of patient enrollment in the DURIPANC Phase 2 clinical trial of Ampligen in combination with AstraZeneca's Imfinzi. The company is optimistic about its future, citing significant clinical and operational milestones.
Read more →AIMAIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones
AIM ImmunoTech has made significant strides in its pancreatic cancer program, particularly with Ampligen, which is currently in the Phase 2 DURIPANC study. The company has achieved key milestones, including completing enrollment and dosing the final patient. Management anticipates a pivotal period ahead, with multiple clinical updates and potential advancements toward Phase 3 planning.
Read more →AIMAIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series
AIM ImmunoTech Inc. announced its participation in the Webull Corporate Connect Webinar Series scheduled for June 24-25, 2026. CEO Thomas Equels will present during the event, discussing the company's advancements and its lead product, Ampligen, which is aimed at treating late-stage pancreatic cancer. The webinar offers a platform for AIM to engage with investors and stakeholders.
Read more →AIM▼ -5%on this newsshared move
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
AIM ImmunoTech has reached a significant milestone in its Phase 2 DURIPANC study for metastatic pancreatic cancer, with the final subject receiving their first dose. The study evaluates Ampligen in combination with AstraZeneca's Imfinzi, aiming to assess clinical benefit rates and overall survival. Primary endpoint analysis is expected in December 2026, with topline results anticipated in Q1 2027.
Read more →AIMAIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
AIM ImmunoTech Inc. has announced its compliance with NYSE American's listing standards after resolving stockholder equity deficiencies. The company raised approximately $8.5 million through warrant exercises and stock sales, ensuring its equity exceeds the minimum requirement. The NYSE American confirmed the removal of the 'below compliance' indicator from AIM's trading symbol.
Read more →AIM▼ -22.3%on this news
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules
AIM ImmunoTech Inc. has announced a registered direct offering and private placement, aiming to raise approximately $2.65 million. The financing will support clinical drug supply, current and planned Phase 3 clinical trial activities, and working capital. The offering is expected to close around June 10, 2026, pending customary conditions.
Read more →AIMAIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
AIM ImmunoTech has reported positive interim results from its Phase 2 study evaluating Ampligen in combination with AstraZeneca's Imfinzi for metastatic pancreatic cancer. The final patient has been enrolled, and the company anticipates a December 2026 evaluation of the primary endpoint. Previous studies suggest Ampligen may significantly improve survival rates compared to standard treatments.
Read more →AIMAIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
AIM ImmunoTech has reported positive interim results from its Phase 2 study evaluating Ampligen in combination with AstraZeneca's Imfinzi for treating pancreatic cancer. The final patient has been enrolled, and results suggest promising survival outcomes. The study aims to assess the Clinical Benefit Rate, with a pivotal Phase 3 trial planned for future evaluation.
Read more →AIM▼ -19.2%on this news· ran to -45% by day 3shared move
AIM ImmunoTech Releases Virtual Investor ‘What This Means’ Video Segment Discussing Ampligen’s Potential in Ebola Virus Disease Preparedness
AIM ImmunoTech has released a video segment discussing the potential of Ampligen in addressing the Bundibugyo Ebola outbreak. The segment highlights the lack of approved therapies for this strain and presents Ampligen's immune-modulating properties, supported by preclinical findings. The company emphasizes the need for preparedness against emerging viral threats and showcases its regulatory achievements.
Read more →AIM▼ -19.2%on this news· ran to -45% by day 3shared move
AIM ImmunoTech Releases Virtual Investor ‘What This Means’ Video Segment Discussing Ampligen’s Potential in Ebola Virus Disease Preparedness
AIM ImmunoTech has released a virtual investor video discussing Ampligen's potential in addressing the Bundibugyo Ebola outbreak. The video features key management discussing the lack of approved therapies for this strain and highlights Ampligen's immune-modulating properties. Previous research indicates that Ampligen could provide prophylactic benefits against Ebola, supporting its potential use in public health preparedness.
Read more →AIM▲ +120.4%on this newsshared move
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones
AIM ImmunoTech has completed enrollment for its Phase 2 DURIPANC study ahead of schedule, focusing on the treatment of metastatic pancreatic cancer with Ampligen and AstraZeneca's Imfinzi. The final subject is expected to begin treatment in mid-June, with results anticipated by December 2026. This milestone reinforces the company's commitment to addressing critical needs in pancreatic cancer treatment.
Read more →AIM▲ +72.4%on this news· ran to +286% by day 3shared move
AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration
AIM ImmunoTech announced promising pre-clinical findings for Ampligen as a potential treatment for Ebola virus disease amid a WHO-declared emergency. The study showed 100% survival in mice following early treatment with Ampligen. The company will present further details in a virtual segment on June 4, highlighting its mechanism of action and potential therapeutic pathways.
Read more →AIM▼ -38.4%on this news
AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement
AIM ImmunoTech has announced a financing deal worth $2.4 million through a registered direct offering and a concurrent private placement. The company will issue approximately 7.5 million shares at a price of $0.325 per share. The proceeds will be used for clinical drug supply manufacturing, planned Phase 3 trial activities, and working capital.
Read more →AIMAIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities
AIM ImmunoTech has reported a significant increase in stockholder equity, rising to approximately $2.1 million as of March 31, 2026, from a deficit of $9.8 million in December 2025. The company has also extended the maturity date of its promissory note with Streeterville Capital to June 30, 2027, enhancing its financial flexibility. This strategic move supports AIM's focus on advancing its pancreatic cancer program and other initiatives aimed at maximizing long-term stockholder value.
Read more →AIMAIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer
AIM ImmunoTech has shared positive data from its Named Patient Program and interim results from its ongoing Phase 2 clinical trial of Ampligen for late-stage pancreatic cancer. The Virtual Investor KOL Connect segment features insights from Professor van Eijck, emphasizing Ampligen's promising immunotherapeutic approach and significant improvements in patient survival rates. The company anticipates further milestones in the coming months.
Read more →AIM▼ -39.7%on this news· ran to -52% by day 3
AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds
AIM ImmunoTech, Inc. announced an agreement to exercise warrants for approximately $4.2 million in gross proceeds. The company will issue up to 8,719,928 shares at a reduced price of $0.48 per share. The funds will be utilized for working capital and general corporate purposes. The offering is expected to close on May 8, 2026.
Read more →AIM▲ +16.4%on this news· ran to -40% by day 3shared move
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential
AIM ImmunoTech announced a 50% Objective Response Rate in a Phase 2 clinical trial for recurrent ovarian cancer, conducted in collaboration with Merck. The trial showed promising results, including a median overall survival of 32.5 months and no severe toxicities. The findings suggest that Ampligen may enhance the effectiveness of checkpoint inhibitors in treating this cancer type.
Read more →AIMAIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP
AIM ImmunoTech is moving forward with a planned Phase 3 study of Ampligen for pancreatic cancer, following encouraging results from Phase 2 trials. The company has secured Orphan Drug Designations in both the U.S. and EU, enhancing its market position. Collaborations with Thermo Fisher Scientific and AstraZeneca bolster its clinical development efforts. AIM's strong intellectual property portfolio further supports its strategy in this high-need therapeutic area.
Read more →AIMAIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP
AIM ImmunoTech is progressing with its pancreatic cancer program, planning a Phase 3 trial for Ampligen, bolstered by encouraging Phase 2 data and a strong IP portfolio. The therapy has received Orphan Drug Designations in the U.S. and EU, enhancing its potential market exclusivity. AIM's collaboration with Thermo Fisher Scientific aims to support the trial design, potentially accelerating development. Moreover, there are positive indications of improved survival rates from ongoing studies, making Ampligen a promising candidate in a critical medical field.
Read more →AIMAIM ImmunoTech Provides Routine Update on Annual Filings
AIM ImmunoTech has provided an update on its annual filings, revealing an audit report that noted a going concern emphasis. Despite this, management remains optimistic about the potential of Ampligen in treating late-stage pancreatic cancer, citing promising results in a Phase 2 clinical trial. The company expects to provide further updates on this study in June 2026. This disclosure is mandated by NYSE regulations and is not an indication of any changes to previous filings.
Read more →AIM▼ -6.2%on this newsshared move
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event
AIM ImmunoTech announced that CEO Tom Equels will participate in a Virtual Investor Closing Bell Event on April 16, 2026. The event will include a corporate overview and a live Q&A session for investors. A webcast of the presentation will be available on the company's website and can be accessed for 90 days after the event.
Read more →AIM▲ +43.7%on this news
AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors
AIM ImmunoTech Inc. announced the final approval of a Japanese patent that covers the use of its proprietary drug Ampligen in combination with checkpoint inhibitors for cancer treatment. This patent, effective until December 2039, allows for treatment across multiple cancer types, particularly late-stage pancreatic cancer. AIM plans to expand its intellectual property portfolio by seeking orphan drug designation in Japan. While the patent represents a significant step forward for the company, AIM highlights that extensive testing is still required to validate the drug's effectiveness.
Read more →AIMAIM ImmunoTech Announces Closing of its Rights Offering
AIM ImmunoTech Inc. has successfully closed its rights offering, raising approximately $1.8 million. Each subscription unit included one share of Series G Convertible Preferred Stock and 2,000 Class G Common Stock Purchase Warrants. The company continues to focus on developing Ampligen for late-stage pancreatic cancer, which remains a critical health challenge.
Read more →AIMAIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million
AIM ImmunoTech Inc. announced the preliminary results of its rights offering, which generated about $1.8 million in subscriptions. The offering expired on March 3, 2026, and the company expects to close it on or around March 6, 2026. Each subscription unit includes shares of Series G Convertible Preferred Stock and warrants for common stock. The results are preliminary and pending final verification.
Read more →AIM▼ -14.9%on this news· ran to -29% by day 3shared move
AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer
AIM ImmunoTech has signed an agreement with Thermo Fisher Scientific to plan a Phase 3 clinical trial for Ampligen in treating late-stage pancreatic cancer. The ongoing Phase 2 DURIPANC trial is yielding promising results, prompting AIM to advance its development strategy. The company emphasizes the potential of Ampligen as a significant therapeutic option for this deadly disease.
Read more →AIM▼ -8.3%on this news· ran to -30% by day 3shared move
AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering
AIM ImmunoTech Inc. has announced updated terms for its rights offering, allowing stockholders to purchase units consisting of preferred stock and warrants. The offering is set to expire on March 3, 2026, and is intended to raise funds for the development of Ampligen for treating late-stage pancreatic cancer. Subscription rights are non-transferable and must be exercised before the deadline.
Read more →AIMAIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026
AIM ImmunoTech has extended the subscription period for its rights offering to March 3, 2026. The rights offering, which began on February 11, 2026, allows holders to subscribe to purchase units. Subscription rights are non-transferable and must be exercised by the expiration date. AIM's lead product, Ampligen, targets late-stage pancreatic cancer.
Read more →AIMAIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer
AIM ImmunoTech has outlined key milestones for its Phase 2 trial of Ampligen combined with AstraZeneca's durvalumab in treating metastatic pancreatic cancer. Enrollment is ongoing, with 18 subjects participating. The study aims to evaluate clinical benefit rates and overall survival, with interim reports planned for mid-year and year-end. The trial has shown promising safety and quality of life outcomes.
Read more →AIMAIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer
AIM ImmunoTech announced milestones for its Phase 2 trial of Ampligen combined with AstraZeneca's durvalumab for metastatic pancreatic cancer. The ongoing DURIPANC study has enrolled 18 subjects, with interim progress reports expected mid-year and year-end. Initial results indicate promising survival rates and a favorable safety profile, with detailed data anticipated later this year.
Read more →AIM▲ +58.2%on this news
CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering
AIM ImmunoTech has commenced a rights offering to raise up to $12 million, allowing existing shareholders to purchase units consisting of preferred stock and warrants. The subscription rights will expire on February 27, 2026, and are non-transferable. The company has engaged Maxim Group LLC as dealer-manager for the offering and has provided details for interested parties to obtain further information.
Read more →AIM▼ -13.5%on this newsshared move
AIM ImmunoTech Announces Commencement of Rights Offering
AIM ImmunoTech has announced the commencement of a rights offering to raise up to $12 million. Shareholders will receive subscription rights to purchase units consisting of preferred stock and warrants. The offering is aimed at supporting the development of Ampligen for late-stage pancreatic cancer. The subscription period runs until February 27, 2026, unless extended.
Read more →AIM▼ -7.3%on this news· ran to -31% by day 3shared move
AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
AIM ImmunoTech will participate in the Corporate Connect Webinar Series hosted by Webull Financial on February 10-11, 2026. CEO Thomas K. Equels will present a corporate overview and discuss the company's strategic focus on pancreatic cancer. This participation underscores AIM's commitment to addressing significant health challenges through innovative therapies.
Read more →AIM▲ +16.6%on this newsshared move
AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
AIM ImmunoTech has reported positive interim results from its Phase 2 study of Ampligen combined with AstraZeneca's Imfinzi for treating metastatic pancreatic cancer. The study, which involves patients with stable disease post-FOLFIRINOX, shows promising survival rates and quality of life improvements. The ongoing research aims to further explore the efficacy and safety of this combination therapy.
Read more →AIM▲ +16.6%on this newsshared move
AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
AIM ImmunoTech has reported positive interim results from its Phase 2 study evaluating Ampligen in combination with AstraZeneca's Imfinzi for metastatic pancreatic cancer. The study shows promising survival rates and improved quality of life for patients. The ongoing trial aims to enroll 25 subjects, with encouraging safety profiles noted. AIM's patent protection and orphan drug designations further support its market potential.
Read more →AIMAIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering
AIM ImmunoTech has announced changes to the key dates and terms of its Rights Offering, which is expected to raise $12 million. The subscription period is set from February 11 to February 27, 2026, with an over-subscription privilege for participants. The funds will be used for clinical trial expenses and to repay existing debts.
Read more →AIMAIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering
AIM ImmunoTech Inc. has announced a rights offering aimed at raising $12 million to support its clinical trials and repay existing debt. The offering will allow shareholders to purchase units consisting of preferred stock and warrants. Key dates include a record date of February 4, 2026, and a subscription period from February 5 to February 23, 2026.
Read more →AIMAIM ImmunoTech Announces Stock Dividend
AIM ImmunoTech Inc. announced a stock dividend of one share for every 1,000 outstanding shares and options or warrants. This dividend will benefit stockholders of record as of January 9, 2026, and will be distributed on January 13, 2026. Fractional shares will be rounded down, and cash will be provided instead for any remaining fractions. AIM is focused on developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19.
Read more →AIMAIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Inc. announced the release of the latest segment of their CEO Corner, featuring discussions led by CEO Thomas Equels. The segment highlights the ongoing clinical evaluation of their lead program, Ampligen® (rintatolimod), in the DURIPANC Phase 1b/2 trial, particularly its combination with AstraZeneca's Imfinzi® (durvalumab). The company's focus on addressing unmet needs in pancreatic cancer through innovative therapies is a central theme of the segment.
Read more →AIMAIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell Series
AIM ImmunoTech's CEO, Thomas K. Equels, will participate in a fireside chat on December 4, 2025, focusing on the company's clinical and regulatory strategies. The discussion will highlight the DURIPANC clinical trial involving Ampligen and AstraZeneca's Imfinzi for metastatic pancreatic cancer, as well as a successful Phase 2 trial with Merck's Keytruda for ovarian cancer. The event will include a Q&A session and a live video webcast.
Read more →AIMAIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell Series
AIM ImmunoTech Inc. will participate in the Virtual Investor Closing Bell Series on December 4, 2025. CEO Thomas K. Equels will discuss the company's clinical and regulatory strategies, particularly focusing on the DURIPANC trial with AstraZeneca and outcomes from a Phase 2 trial with Merck's Keytruda. The webcast will allow for audience interaction through pre-submitted questions and will be available for replay shortly after the live presentation. This engagement aims to highlight the company's lead product, Ampligen, and its ongoing research in cancer treatment.
Read more →AIM▼ -7.6%on this news
AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program
AIM ImmunoTech has reported its third quarter 2025 financial results, highlighting progress in its clinical programs, particularly in pancreatic cancer. The company received positive safety and efficacy data from its DURIPANC trial, showing potential in combination therapy with AstraZeneca's Imfinzi. Financially, AIM has reduced its operating expenses compared to the previous year but still reported a net loss. Additionally, AIM has recently secured patents to strengthen its position within the oncology space, focusing on Ampligen as a treatment option for various conditions.
Read more →AIM▼ -6.4%on this news
AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer
AIM ImmunoTech presented positive results from a Phase 2 clinical trial of Ampligen in advanced recurrent ovarian cancer at the SITC Meeting. The study showed a 50% objective response rate, significantly higher than previous pembrolizumab-only studies. This suggests Ampligen may enhance the effectiveness of traditional cancer treatments, particularly for patients with limited options.
Read more →AIM▼ -6.4%on this newsshared move
AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer
AIM ImmunoTech presented data from a Phase 2 clinical trial on Ampligen for advanced recurrent ovarian cancer at the SITC Meeting. The trial showed a 50% Objective Response Rate among evaluable patients, significantly higher than previous studies with pembrolizumab alone. The findings suggest Ampligen may enhance the effectiveness of traditional cancer treatments.
Read more →AIM▼ -20.4%on this news
AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
AIM ImmunoTech announced that data from its Phase 2 study on Ampligen for cisplatin-resistant advanced recurrent ovarian cancer has been accepted for a late-breaking abstract presentation at the 40th Annual SITC Meeting. The study aims to explore the correlation between T lymphotactic response and clinical outcomes. The presentation will take place on November 7, 2025.
Read more →AIMAIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue
AIM ImmunoTech has received a European patent for Ampligen (rintatolimod) aimed at treating Long COVID. This patent strengthens their intellectual property portfolio and supports the efficacy of Ampligen, which has shown promise in reducing fatigue in patients with post-COVID conditions. The company continues to focus on its pancreatic cancer clinical program while exploring Ampligen's potential in broader applications.
Read more →AIMAIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue
AIM ImmunoTech announced the granting of a European patent for Ampligen (rintatolimod) aimed at treating Long COVID. This patent enhances AIM's intellectual property portfolio and supports the efficacy of Ampligen, which has shown promising results in a Phase 2 study for post-COVID fatigue. The company continues to focus on its pancreatic cancer clinical program while exploring Ampligen's broader therapeutic potential.
Read more →AIMAIM ImmunoTech to Attend the 2025 Maxim Growth Summit
AIM ImmunoTech Inc. announced its participation in the 2025 Maxim Growth Summit in New York on October 22-23, 2025. The event will feature industry leaders and provide opportunities for investor meetings. AIM's lead product, Ampligen, is currently in Phase 2 clinical trials for metastatic pancreatic cancer in collaboration with AstraZeneca.
Read more →AIMAIMイムノテック (AIM ImmunoTech)、アンプリジェン (Ampligen®)(リンタトリモド) とチェックポイント阻害剤を併用する新規がん治療に関する特許を日本で2039年まで取得
AIM ImmunoTech has announced the approval of its drug Ampligen® for use in treating certain conditions until 2039. This approval is expected to bolster the company's market presence and financial stability. AIM plans to leverage this opportunity to enhance its research and development efforts in the biopharma sector. The approval highlights the company's commitment to addressing significant medical needs.
Read more →AIMAIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors
AIM ImmunoTech has secured a patent in Japan for its cancer therapy combining Ampligen (Rintatolimod) with checkpoint inhibitors, valid until December 2039. This patent enhances AIM's intellectual property portfolio in a major oncology market and supports its clinical development strategy. The combination therapy shows promise in treating difficult cancers, with ongoing clinical trials indicating positive outcomes.
Read more →AIMAIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors
AIM ImmunoTech has received a patent from the Japan Patent Office for its cancer therapy combining Ampligen® (Rintatolimod) with checkpoint inhibitors, valid until December 2039. This patent strengthens AIM's intellectual property in a significant oncology market and supports its strategic collaborations. The combination therapy aims to improve treatment outcomes for various challenging cancers.
Read more →AIM▲ +6.2%on this newsshared move
AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth
AIM ImmunoTech announced the publication of a peer-reviewed article in the Journal for ImmunoTherapy of Cancer, demonstrating the positive effects of its drug Ampligen combined with interferon-alpha on tumor growth and patient survival. The study suggests that reprogramming the tumor microenvironment could enhance the effectiveness of immune checkpoint inhibitors. This publication highlights the therapeutic potential of AIM's approach to treating cold tumors.
Read more →AIMAIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland
AIM ImmunoTech presented promising data on Ampligen for pancreatic cancer at the 5th Annual Marie Skłodowska-Curie Symposium. The drug showed potential in improving Progression-Free Survival and Overall Survival in ongoing trials. The company remains committed to advancing Ampligen's development, addressing a critical unmet need in treating late-stage pancreatic cancer.
Read more →AIMAIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update
AIM ImmunoTech reported positive developments in its second quarter 2025 financial results, highlighting progress in its Phase 2 trial of Ampligen for pancreatic cancer. The combination therapy with AstraZeneca's Imfinzi shows promising results with no significant toxicity. The company also noted a strong cash position, allowing operations to continue for approximately 12 months.
Read more →AIMAIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
AIM ImmunoTech Inc. will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech from August 19-21, 2025. The presentation is scheduled for August 20, 2025, at 2:40 PM ET, with CEO Thomas Equels as the presenter. The event highlights AIM's focus on immuno-pharmaceutical advancements, including their lead investigational drug, Ampligen.
Read more →AIMAIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)
AIM ImmunoTech's drug Ampligen will be featured in multiple presentations at the 5th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care. The presentations will highlight Ampligen's clinical successes in pancreatic cancer and its potential benefits for endometriosis. Preliminary data from the DURIPANC study indicates promising survival outcomes for patients with late-stage metastatic pancreatic cancer. The symposium aims to accelerate the development of innovative cancer treatments.
Read more →AIM▲ +6.4%on this newsshared move
AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval
AIM ImmunoTech is focusing on advancing its clinical trials for Ampligen® in pancreatic cancer, following a positive mid-year report indicating no significant toxicity and improved patient outcomes. The company has secured $8 million in funding, which will support operations for approximately 12 months. Despite challenges, AIM is optimistic about the drug's potential and its path toward regulatory approval.
Read more →AIM▲ +6.4%on this newsshared move
AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen Clinical Development Toward Pancreatic Cancer Approval
AIM ImmunoTech Inc. has emphasized its commitment to advancing the clinical development of its drug Ampligen® for pancreatic cancer, following a positive mid-year report. They reported promising outcomes in a Phase 2 study in combination with AstraZeneca's Imfinzi® and highlighted recent financial achievements, including a successful equity offering. With regained market status and new patent approvals, the company aims to bolster its position towards achieving drug approval.
Read more →AIMAIM ImmunoTech Announces Closing of $8.0 Million Public Offering
AIM ImmunoTech Inc. announced the successful closing of an $8.0 million public offering, involving 2 million shares of common stock and accompanying warrants. The securities were offered at a price of $4.00 per share, with gross proceeds expected before expenses. Maxim Group LLC served as the sole placement agent for the offering. AIM ImmunoTech focuses on developing therapeutics for multiple types of cancers and viral diseases, including its lead investigational drug Ampligen®.
Read more →AIM▼ -56.2%on this newsshared move
AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering
AIM ImmunoTech Inc. has announced a public offering of 2,000,000 shares of its common stock, priced at $4.00 each, aiming to raise approximately $8.0 million. The offering also includes Class E and Class F warrants, with specific expiration terms. The closing of the offering is anticipated on or about July 30, 2025, subject to standard conditions. This initiative aligns with AIM's commitment to developing therapeutics for cancer, immune disorders, and viral diseases.
Read more →AIM▼ -14.3%on this newsshared move
AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
AIM ImmunoTech has reported positive mid-year results from its Phase 2 study evaluating Ampligen in combination with AstraZeneca's Imfinzi for treating pancreatic cancer. The study shows promising safety and efficacy data, with a significant percentage of patients achieving progression-free survival beyond six months. The ongoing research aims to personalize therapy and improve outcomes for this challenging cancer type.
Read more →AIM▼ -14.3%on this newsshared move
AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
AIM ImmunoTech has reported positive mid-year data from its Phase 2 study evaluating Ampligen combined with AstraZeneca’s Imfinzi for metastatic pancreatic cancer. The early results indicate that the treatment is well-tolerated and shows promising survival benefits, with 64% of treated patients achieving overall survival beyond six months. The study's focus on patient-specific outcomes aims to enhance the therapeutic approach in this challenging disease area. The potential effectiveness of this combination therapy represents a significant step forward in addressing the high unmet medical need in pancreatic cancer treatment.
Read more →AIMAIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies
AIM ImmunoTech announced a presentation by Dr. Pawel Kalinski on Ampligen at the U.S.-Poland Science and Technology Symposium held in June 2025. The discussion focused on the potential outcomes of private-public partnerships in oncology research, emphasizing collaborative clinical trials. CEO Thomas K. Equels highlighted plans to establish further partnerships and licensing agreements, particularly with an eye on initiatives in Poland and Central Eastern Europe. This represents AIM's strategic approach to advancing their cancer therapies through innovative funding and research collaborations.
Read more →AIMAIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders’ Equity Requirements
AIM ImmunoTech received a notice from NYSE American for noncompliance with minimum stockholders' equity requirements, as the company reported a deficit of $3.9 million as of March 31, 2025. AIM has until June 11, 2026, to regain compliance, following a previously accepted plan. Despite this, the company's stock resumed trading on June 17, 2025.
Read more →AIM▲ +11%on this newsshared move
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders’ Equity Requirements
AIM ImmunoTech Inc. has been notified by NYSE American of noncompliance with minimum stockholders’ equity requirements due to a deficit of $3.9 million as of March 31, 2025. This deficiency follows a prior notice issued in December 2024 for the same reason. The company has until June 11, 2026, to regain compliance. Despite the notice, AIM's stock resumed trading under the symbol 'AIM' on June 17, 2025, and the notification does not affect its business operations or SEC reporting requirements.
Read more →AIM▲ +10596.1%on this newsshared move
AIM ImmunoTech Resumes Trading on NYSE American
AIM ImmunoTech Inc. has announced that its common stock is resuming trading on the NYSE American under the symbol 'AIM' from June 17, 2025. The company specializes in the development of immunotherapeutics targeting various cancers, immune disorders, and viral diseases, including COVID-19. Its lead product, Ampligen, is currently undergoing clinical trials and is recognized as a novel immuno-modulator. The announcement highlights the company's ongoing commitment to advancing its pipeline amid a dynamic market landscape.
Read more →AIM▲ +10596.1%on this newsshared move
AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen
AIM ImmunoTech has received a U.S. patent for the manufacturing methods of therapeutic double-stranded RNA (dsRNA), including its drug Ampligen, which extends patent protection until January 2041. This patent bolsters AIM's intellectual property portfolio and provides a secure development runway for the drug. The company is actively seeking FDA approval for Ampligen across various indications, though future success is not guaranteed as clinical trials continue. AIM's patents also include several orphan drug designations that may aid in market exclusivity post-approval.
Read more →AIM▲ +10596.1%on this newsshared move
AIM ImmunoTech Announces NYSE American Removal of Trading Suspension
AIM ImmunoTech Inc. announced that the NYSE Regulation has lifted the trading suspension of its stock on the NYSE American. This decision was based on the stock's performance exceeding the low selling price issues defined by the NYSE guidelines. The company’s common stock is set to resume trading on June 17, 2025, under the symbol 'AIM'. AIM ImmunoTech focuses on developing therapeutics for various cancers and viral diseases.
Read more →AIM▲ +10596.1%on this newsshared move
AIM ImmunoTech Announces 1-for-100 Reverse Stock Split
AIM ImmunoTech Inc. has announced a 1-for-100 reverse stock split that will take effect on June 12, 2025, to raise the per-share market price and regain compliance with NYSE American Listing Qualifications. The reverse stock split follows approval from shareholders during a special meeting held on April 30, 2025. The adjusted ticker symbol during this period will be AIMID, and stockholders will receive cash for any fractional shares. AIM is focused on developing immunotherapies, including its lead product Ampligen.
Read more →AIM▲ +10596.1%on this newsshared move
AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists
AIM ImmunoTech Inc. announced the presentation of clinical trial data for its drug Ampligen at the recent Annual Meeting of the American Association of Immunologists. The data, presented by Dr. Pawel Kalinski, demonstrated Ampligen's ability to selectively attract CTLs into tumor microenvironments while avoiding undesirable inflammatory responses. AIM's CEO expressed confidence in Ampligen's potential as a treatment for serious cancers. However, the company cautioned that clinical success does not guarantee future therapy approval.
Read more →AIM▲ +10596.1%on this newsshared move
AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market
AIM ImmunoTech has announced that its common stock is now trading under the ticker AIMI on the Pink Open Market. The company is focused on developing therapies for multiple cancers, immune disorders, and viral diseases, including COVID-19. A special meeting concerning a reverse stock split is scheduled for April 30, 2025. Despite the announcements, potential risks relating to the approval and success of its lead product, Ampligen, remain.
Read more →AIM▼ -19.4%on this news· ran to +8522% by day 1shared move
AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal
AIM ImmunoTech Inc. announced on April 4, 2025, that it received a notice from the NYSE American regarding the suspension of trading of its common stock. The suspension is due to the low selling price of the stock, leading to the commencement of delisting proceedings. The company intends to appeal this decision to the Listing Qualifications Panel, although there is no guarantee that the appeal will be successful. Following the suspension, the company's stock is expected to begin trading on the Pink Open Market on April 7, 2025.
Read more →AIMAIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
AIM ImmunoTech Inc. has reported its financial results for the fourth quarter and full year of 2024, alongside a corporate update. The company disclosed progress in clinical development programs, notably in pancreatic cancer and its collaboration with AstraZeneca and Merck for ongoing trials. AIM's cash reserves have declined compared to the previous year, prompting concerns over financial stability. Upcoming milestones are anticipated to provide value-driving opportunities in the next 18 months, although uncertainties remain regarding the success of its drug Ampligen.
Read more →AIMAIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ’25” On-Demand Conference
AIM ImmunoTech Inc. participated in the Virtual Investor 'Top 5 for ’25' On-Demand Conference, where CEO Thomas K. Equels highlighted key advancements in the company's clinical trials. These include progress in pancreatic cancer treatment, research in ME/CFS, and plans for Ampligen as a vaccine adjuvant for bird flu. The on-demand webcast is available on their website.
Read more →AIMAIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
AIM ImmunoTech Inc. participated in the Virtual Investor 'Top 5 for '25' On-Demand Conference, where CEO Thomas K. Equels highlighted key advancements and research. Notable updates include progress in pancreatic cancer treatment through the DURIPANC trial and ongoing studies in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome related to COVID-19. The company is also advancing its oncology initiatives and plans to utilize Ampligen as a vaccine adjuvant for bird flu as part of its antiviral pipeline.
Read more →AIM▲ +5.6%on this news
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza
AIM ImmunoTech has appointed Dr. Paul Goepfert as the Principal Investigator for a clinical study combining Ampligen and FluMist as an intranasal vaccine for avian influenza. This study follows promising results from prior research, indicating enhanced immune responses. AIM is seeking funding to advance the study, emphasizing the potential for a rapid and cost-effective vaccine development.
Read more →AIM▲ +5.6%on this newsshared move
contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Words such as "may," "will," "expect," "plan," "anticipate," "continue," "believe," "potential
AIM ImmunoTech Inc. announced that the NYSE American has accepted its plan to regain compliance with stockholder equity requirements. The company has until June 11, 2026, to meet the exchange's standards. CEO Thomas K. Equels expressed optimism towards executing the plan while advancing their oncology and antiviral pipelines. However, the company cautions that there are risks and uncertainties in achieving compliance as stated in their forward-looking disclosures.
Read more →AIM▲ +9.6%on this newsshared move
AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance
AIM ImmunoTech Inc. has announced that the NYSE American has accepted its plan for regaining compliance with the minimum stockholder equity requirements. The company has until June 11, 2026, to meet the NYSE's Continued Listings Standards. CEO Thomas K. Equels expressed optimism about their strategy while also confirming that advancements in their oncology and antiviral pipelines are ongoing. However, the company faces risks regarding the achievement of compliance within the necessary timeframe.
Read more →AIM▲ +9.6%on this newsshared move
AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director
AIM ImmunoTech has appointed David Chemerow as an Independent Director to its Board, effective immediately. Chemerow, who has over 40 years of experience in finance and operations, previously served in executive roles at Comscore and Rentrak. His appointment is seen as a strategic move to enhance AIM's leadership as the company aims for long-term success in the immuno-pharma industry. Chemerow has expressed enthusiasm about contributing to the growth of AIM, particularly in developing Ampligen, its lead investigational drug.
Read more →AIM▼ -7.5%on this newsshared move
AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
AIM ImmunoTech has initiated Phase 2 of its DURIPANC trial, dosing the first new subject. This study evaluates the combination of Ampligen and Imfinzi for late-stage pancreatic cancer. The trial aims to enroll up to 25 patients and is being conducted at the Erasmus Medical Center in the Netherlands. The company expresses confidence in steady enrollment despite common challenges in pancreatic cancer studies.
Read more →AIM▲ +5.8%on this news
AIM ImmunoTech Releases Virtual Investor “What This Means Segment”
AIM ImmunoTech has announced the approval from the Erasmus MC Safety Committee to advance to Phase 2 of the DURIPANC study, which explores the combination of Ampligen and AstraZeneca's Imfinzi for treating late-stage pancreatic cancer. The Phase 1 data indicated that the treatment was generally well-tolerated without severe adverse events. The discussion was led by AIM's CEO and a leading surgeon from Erasmus MC.
Read more →AIM▲ +5.8%on this newsshared move
AIM ImmunoTech Releases Virtual Investor “What This Means Segment”
AIM ImmunoTech has announced the approval from the Erasmus MC Safety Committee to advance to Phase 2 of the DURIPANC clinical trial. The trial investigates the effectiveness of AIM's Ampligen® combined with AstraZeneca's Imfinzi® for treating late-stage pancreatic cancer. AIM's CEO, Tom Equels, and Prof. Casper van Eijck discussed the trial's potential in a recent virtual investor segment. The Phase 1 study's safety data indicated that the treatment combination is generally well-tolerated, showing promise for patient outcomes.
Read more →AIM▲ +5.8%on this newsshared move
AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024
AIM ImmunoTech Inc. announced that it will delay proceeding with its offering as per the Registration Statement on Form S-1 until after filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The company, which focuses on developing therapeutics for various diseases including cancers and viral infections, has made this choice amidst calls for caution regarding forward-looking projections. This decision may affect the company's funding strategies and investor confidence while significant investments are anticipated in their ongoing clinical trials.
Read more →AIMAIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM’s Ampligen® and AstraZeneca’s FluMist® to address the recent avian influenza outbreaks
AIM ImmunoTech has announced plans for a follow-up clinical study evaluating the combination of Ampligen and AstraZeneca's FluMist to combat avian influenza. This initiative follows promising results from earlier studies that indicated enhanced immune responses against avian flu strains. AIM aims to secure funding for the study and believes this combination therapy could offer broader protection against avian flu infections.
Read more →AIMAIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM’s Ampligen and AstraZeneca’s FluMist to address the recent avian influenza outbreaks
AIM ImmunoTech has announced plans for a follow-up clinical study evaluating the combination of its Ampligen treatment with AstraZeneca's FluMist vaccine to combat avian influenza. This new study builds on earlier research indicating that the combination significantly boosts immune response against various strains of the avian flu. AIM is actively working with Amarex Clinical Research to manage the Investigational New Drug application for this potential combination therapy. The company aims to secure grants to support the study amid growing public health concerns regarding avian influenza outbreaks.
Read more →AIMCONFIDENTIAL DRAFT NOT FOR IMMEDIATE RELEASE AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen and AstraZeneca's FluMist to address the recent avian influenz
AIM ImmunoTech announced a plan for a follow-up clinical study evaluating the combination of its drug Ampligen and AstraZeneca's FluMist to tackle avian influenza outbreaks. The study aims to leverage previous clinical findings from the University of Alabama-Birmingham that indicated Ampligen could significantly boost immune responses to seasonal influenza. The company is pursuing government and industry grants to support the study's costs. AIM's CEO emphasized the urgent public health need for a more effective influenza vaccination program, particularly against avian flu.
Read more →AIM▼ -20.8%on this newsshared move
Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen® and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
AIM ImmunoTech Inc. has received approval from the Safety Committee to proceed with the Phase 2 study of its combination therapy, Ampligen and Imfinzi, for late-stage pancreatic cancer. This decision follows positive Phase 1 safety data indicating the therapy was well-tolerated. Enrollment for Phase 2 is expected to start soon, with up to 25 patients anticipated.
Read more →AIM▼ -20.8%on this newsshared move
Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer Safety Committee approval based on positiv
AIM ImmunoTech Inc. announced that the Erasmus Medical Center Safety Committee has granted approval to proceed with the Phase 2 study of Ampligen and Imfinzi as a potential combination therapy for late-stage pancreatic cancer. This decision follows positive results from the Phase 1 trial, which showed that the therapy was well-tolerated and did not result in severe adverse effects. The first Phase 2 enrollment is expected soon, as the company aims to address the high unmet needs in treating metastatic pancreatic cancer.
Read more →AIMAIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions
AIM ImmunoTech announced the publication of final clinical study results for its AMP-518 trial, evaluating the safety and efficacy of Ampligen in patients suffering from Post-COVID conditions. The results indicate significant improvements in patients' ability to walk, particularly among those with moderate to severe symptoms. The study’s findings underscore a pressing need for therapies targeting the rise of ME/CFS associated with COVID-19, revealing an increased prevalence of productive patients. CEO Thomas K. Equels emphasized the importance of addressing the unmet needs of those affected by long COVID.
Read more →AIMAIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS
AIM ImmunoTech recently highlighted a study revealing a substantial link between COVID-19 and an increased incidence of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), with post-infection rates 15 times higher than pre-pandemic levels. The findings indicate that 531 participants met ME/CFS criteria, emphasizing the long-term health implications of COVID-19. AIM believes this data supports their ongoing research and development of Ampligen as a treatment for ME/CFS, particularly in patients with Long COVID. Additionally, early treatment with Ampligen may provide significant benefits for those suffering from symptoms.
Read more →AIMAIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones
AIM ImmunoTech has outlined its achievements over 2024 and set ambitious milestones for 2025-2026, particularly in pancreatic cancer and Long-COVID treatments. The company reported positive data from several clinical studies involving Ampligen, including its use in combination therapies for late-stage pancreatic cancer and recurrent ovarian cancer. AIM's strategy includes funding collaborations with significant partners like AstraZeneca and Merck, highlighting a commitment to addressing critical unmet medical needs. The upcoming milestones suggest strong potential for the company to drive significant shareholder value.
Read more →AIMAIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting
AIM ImmunoTech Inc. announced the re-election of three incumbent directors and the election of Ted D. Kellner to its Board of Directors during the 2024 Annual Meeting of Stockholders. Chairman Dr. William M. Mitchell expressed gratitude to shareholders for their support and emphasized the board's commitment to advancing their lead drug candidate, Ampligen. The results are preliminary until certified by the independent Inspector of Elections.
Read more →AIMAIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
AIM ImmunoTech Inc. announced it received a notice from NYSE American indicating noncompliance with continued listing standards. The company must submit a compliance plan by January 10, 2025, to regain compliance by June 11, 2026. The notice does not immediately impact the trading of AIM's shares, which will continue to be listed and will carry a designation indicating its below-compliance status. If AIM fails to submit an acceptable plan or achieve compliance, it may face delisting procedures.
Read more →AIMAIM ImmunoTech Reminds Shareholders to Vote “FOR” All Four Incumbent Board Members on the WHITE Universal Proxy Card
AIM ImmunoTech is urging shareholders to vote for its four incumbent board members in the upcoming Annual Meeting scheduled for December 17, 2024. The company believes that the current board is best positioned to oversee the clinical development of its lead drug, Ampligen. AIM warns that allowing an activist group to take control could risk the company's progress and financial stability.
Read more →AIMAIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card “FOR” All Four Incumbent Board Members
AIM ImmunoTech is urging shareholders to vote for the re-election of its four incumbent board members ahead of the upcoming Annual Meeting. The company argues that the current board is essential for maintaining clinical momentum and commercializing its lead product, Ampligen. AIM criticizes the activist group's reimbursement demands and questions the qualifications of their nominees, highlighting recommendations from proxy advisory firms against the activist group's control.
Read more →AIMAIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue
AIM ImmunoTech has received a new patent from the Netherlands Patent Office covering its drug Ampligen for treating post-COVID fatigue. The company has reported positive topline results from a Phase 2 trial, suggesting potential efficacy in reducing fatigue among affected individuals. This patent addition is part of AIM's broader strategy to expand its intellectual property domain, which also includes patents for various cancer treatments and chronic fatigue syndrome. Notably, AIM conducts much of its European research at the Erasmus Medical Center, reinforcing its commitment to innovative therapeutic solutions.
Read more →AIMGlass Lewis Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan, Thomas K. Equels and Dr. William M. Mitchell
AIM ImmunoTech has received recommendations from Glass Lewis and ISS to vote for its board nominees in the upcoming Annual Meeting. The advisory firms criticized the Activist Group's lack of a detailed plan and questioned the qualifications of its nominees. AIM urges shareholders to support its current board to ensure continued progress.
Read more →AIMAIM ImmunoTech Participates in Virtual Investor KOL Connect Segment
AIM ImmunoTech Inc. announced the release of a Virtual Investor KOL Connect segment featuring Dr. Charles Lapp, the Company's Consulting Medical Officer. Dr. Lapp discussed the findings from AIM's Phase 2 study on Ampligen® as a potential treatment for Post-COVID fatigue. The segment underscores AIM's efforts to engage investors and highlight ongoing research in chronic conditions. AIM ImmunoTech focuses on developing therapeutics for various diseases, including cancers and viral infections.
Read more →AIMISS Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan and Dr. William M. Mitchell
AIM ImmunoTech Inc. announced that ISS has recommended shareholders vote for its nominees, Nancy K. Bryan and Dr. William M. Mitchell, in the upcoming Annual Meeting. ISS criticized the activist group's plan as limited and raised concerns about the backgrounds of their nominees. AIM urges shareholders to support its board to safeguard the company’s future.
Read more →AIM▼ -5.7%on this newsshared move
AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group’s Nominees to the Board
AIM ImmunoTech has issued a presentation urging shareholders to reject the activist group's nominees for the Board of Directors. The company highlights the nominees' questionable backgrounds, including past mismanagement and associations with convicted felons. AIM warns that the activist group plans to seek reimbursement for over $5 million in litigation expenses without shareholder approval. The company encourages shareholders to vote for its incumbent candidates at the upcoming Annual Meeting.
Read more →AIMAIM ImmunoTech Refutes Activist Group’s False and Misleading Claims
AIM ImmunoTech has issued a statement countering claims made by an activist group attempting to take control of its Board. The company emphasizes its commitment to long-term shareholder value and refutes allegations regarding its historical share price. AIM urges shareholders to support its incumbent Board candidates in the upcoming Annual Meeting.
Read more →AIMAIM ImmunoTech Announces Cash Conservation Plan
AIM ImmunoTech has announced a Cash Conservation Plan aimed at enhancing shareholder value by aligning compensation with company stock. Independent directors will now receive their compensation entirely in AIM stock, while executive salaries will also be partially converted to stock. The company emphasizes its commitment to advancing its clinical pipeline, particularly in oncology, despite recent declines in shareholder value.
Read more →AIMAIM ImmunoTech Announces Cash Conservation Plan Independent Board Members to Receive 100% of Director Compensation in AIM Stock Follows Previously Disclosed Amendments to Executive Employment Agreements to Reduce Cash Co
AIM ImmunoTech has announced the establishment of a Cash Conservation Plan aimed at enhancing its financial sustainability and maintaining progress in key clinical developments. Under this plan, independent board members will receive their compensation exclusively in AIM stock instead of cash. Additionally, significant salary reductions have been implemented for the CEO and COO, redirecting those funds towards stock compensation. The company's leadership emphasizes the importance of increasing shareholder value through the advancement of Ampligen, particularly in oncology.
Read more →AIMAIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders
AIM ImmunoTech has released a presentation urging shareholders to re-elect its current board members ahead of the 2024 Annual Meeting. The company highlights positive data from its clinical pipeline and partnerships with major pharmaceutical firms as key drivers for future value. AIM warns that the activist group poses risks to its clinical progress and financial stability.
Read more →AIM▼ -20.6%on this news
AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer
AIM ImmunoTech Inc. announced the publication of data from a Phase 1 study on its drug, Ampligen, in combination with a chemokine-modulating regimen for early-stage triple-negative breast cancer (TNBC). Conducted at Roswell Park Comprehensive Cancer Center, the study reported promising results that suggest Ampligen could modify the tumor microenvironment. Although the findings are encouraging, further validation in larger studies is necessary. AIM's CEO expressed optimism for Ampligen's role in conjunction with various therapies as the study advances to Phase 2.
Read more →AIM▼ -11.7%on this newsshared move
AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update
AIM ImmunoTech Inc. reported its third quarter 2024 financial results, highlighting progress in its Ampligen® clinical development programs, particularly for pancreatic cancer. The company announced positive preliminary findings from studies on Ampligen in combination with Imfinzi and also noted potential benefits for long-COVID patients. AIM has been executing its clinical strategy effectively, with ongoing collaborations with big pharma and newly secured patents. Financially, the company demonstrated reduced operational losses compared to the previous year, suggesting improved fiscal management.
Read more →AIMAIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast
AIM ImmunoTech Inc. has announced a conference call and webcast scheduled for November 15, 2024, to discuss its operational and financial results for the third quarter of 2024. The call will feature the company’s leadership, including CEO Thomas K. Equels and Scientific Officer Christopher McAleer. Participants can join the call by phone or via a webcast on the company's website, which will be available for 90 days post-event.
Read more →AIMAIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders
AIM ImmunoTech has filed its definitive proxy statement ahead of the 2024 Annual Meeting, urging shareholders to vote for its incumbent board members. The company expresses optimism about its clinical trials for Ampligen, particularly in pancreatic cancer, while warning that an activist group's takeover could jeopardize progress and shareholder value. AIM emphasizes the importance of safeguarding its momentum and strategic direction.
Read more →AIMAIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC
AIM ImmunoTech Inc. has announced that CEO Tom Equels will participate in a fireside chat at the upcoming 2024 Healthcare Virtual Summit on October 16, 2024. The summit, presented by Maxim Group LLC, will feature a variety of biotechnology and healthcare industry discussions. This event is expected to facilitate valuable interaction between CEOs and management of featured companies, potentially benefiting AIM through increased exposure in the biotech community.
Read more →AIMAIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis
AIM ImmunoTech has been granted a U.S. patent for Ampligen® to treat endometriosis, a chronic condition affecting about 6.5 million women in the U.S. The patent covers methods and compositions involving double-stranded RNA products. Experts emphasize the need for effective therapies, as current options have significant side effects. AIM's CEO views this as a milestone for women's health.
Read more →AIMAIM ImmunoTech Granted U.S. Patent for Ampligen for the Treatment of Endometriosis
AIM ImmunoTech Inc. announced the granting of U.S. patent No. 12,102,649 for their drug Ampligen, intended for the treatment of endometriosis. This patent encompasses both the compositions and methods of using Ampligen, a double-stranded RNA product, which could significantly enhance treatment options for the approximately 6.5 million women in the U.S. suffering from this chronic condition. The company plans to leverage this development to improve the quality of life for women suffering from endometriosis and expand its therapeutic portfolio.
Read more →AIMAIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering
AIM ImmunoTech Inc. announced a registered direct offering of 4,653,036 shares of common stock priced at $0.27 per share, which could raise around $1.26 million. In addition to this offering, the company will issue unregistered Class C and Class D warrants for the same number of shares. This fundraising initiative suggests ongoing institutional interest in AIM's developments in immuno-pharmaceuticals, particularly for its lead product, Ampligen. Maxim Group LLC is serving as the placement agent for this offering.
Read more →AIMAIM ImmunoTech Inc.
AIM ImmunoTech Inc. has announced a securities purchase agreement with a single institutional investor, involving a direct offering of over 4.6 million shares at $0.27 each. Alongside this, the company will issue unregistered Class C and Class D warrants for the same number of shares with varying exercise prices and durations. The total estimated proceeds from this dual offering amount to approximately $1.26 million before fees. AIM ImmunoTech continues to focus on the development of therapeutics for cancer, immune disorders, and viral diseases.
Read more →AIMAIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
AIM ImmunoTech Inc. announced that CEO Thomas K. Equels will participate in a Virtual Investor CEO Connect segment on October 2, 2024. The event will include a brief presentation followed by a live Q&A session for investors and stakeholders. A live video webcast will be available with a replay for 90 days, allowing broader access to the company's updates and interactive engagement.
Read more →AIMAIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
AIM ImmunoTech has reported positive preliminary data from its Phase 1b/2 study evaluating the combination of Ampligen and Imfinzi for late-stage pancreatic cancer. In the first cohort, two out of three patients maintained stable disease after six months of treatment. The therapy was well-tolerated, with no severe side effects observed. Continued monitoring of the subjects will provide further insights into the therapy's efficacy and safety.
Read more →AIMAIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen’s Potential to Improve the Post-COVID Condition of Fatigue
AIM ImmunoTech announced that the analysis of AMP-518 clinical trial data supports the potential of Ampligen as a treatment for moderate-to-severe Post-COVID fatigue. Patients treated with Ampligen showed a significant improvement in walking distance compared to the placebo group. AIM plans to focus future trials on this patient population, emphasizing the drug's therapeutic potential.
Read more →AIMAIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen’s Potential to Improve the Post-COVID Condition of Fatigue
AIM ImmunoTech Inc. announced that an analysis of the AMP-518 clinical trial data supports Ampligen's potential as a treatment for moderate-to-severe post-COVID fatigue. The analysis highlighted significant improvements in walking distance for patients taking Ampligen compared to those on placebo. The company aims to focus future clinical trials on patients experiencing moderate to severe fatigue related to Long COVID. Additionally, AIM recently appointed Dr. Charles Lapp as lead Medical Officer to advance development efforts for Ampligen.
Read more →AIM▲ +15.3%on this news· ran to +27% by day 1
AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
AIM ImmunoTech announced the publication of findings from a study on Ampligen for pancreatic cancer in the journal Clinical Cancer Research. The study demonstrated that Ampligen enhances immune responses, correlating with improved patient outcomes. The company is also evaluating Ampligen in ongoing clinical trials for advanced pancreatic cancer. Further commentary highlights its potential benefits and safety in treatment.
Read more →AIM▲ +15.3%on this news· ran to +27% by day 1shared move
AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
AIM ImmunoTech has announced the print publication of a study demonstrating the immune-stimulatory properties of its drug Ampligen in treating pancreatic cancer. The data, published in the journal Clinical Cancer Research, reveals that Ampligen enhances immune activity and correlates with improved clinical outcomes for patients. Ongoing clinical evaluations continue to explore the drug's efficacy as a therapy for metastatic and locally advanced pancreatic cancers. The study highlights Ampligen's potential to modulate expression of key immune checkpoints in the tumor microenvironment.
Read more →AIMAIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
AIM ImmunoTech reported its financial results for Q2 2024, highlighting continued progress in its Ampligen clinical development programs and positive data regarding its anti-tumor potential in melanoma. The company noted a reduction in net loss compared to the previous year, demonstrating operational improvements. However, AIM continues to face significant financial challenges with ongoing research and development costs. The leadership team remains optimistic about Ampligen's potential in various therapeutic areas.
Read more →AIMAIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast
AIM ImmunoTech Inc. will discuss its operational and financial results for the second quarter of 2024 in a conference call scheduled for August 16, 2024. The call will be led by the CEO and the Scientific Officer. Interested investors can participate via a call or online webcast, with the latter being available for 90 days following the event. AIM ImmunoTech specializes in immunotherapy research targeting various health conditions.
Read more →AIM▼ -7.2%on this newsshared move
AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy
AIM ImmunoTech Inc. has announced promising pre-clinical data for its drug Ampligen, showing improved anti-tumor efficacy when used in combination with dendritic cell-based vaccines and anti-PD-L1 checkpoint inhibitors in melanoma treatment. The findings, published in the journal Vaccines, suggest a potential pathway for Ampligen's development as an anti-tumor therapy. However, the company cautions that pre-clinical success does not ensure future commercial approval.
Read more →AIM▼ -6.4%on this news
AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
AIM ImmunoTech Inc. will be participating in the Virtual Investor Pitch Conference on June 17, 2024. CEO Thomas K. Equels is set to present an elevator pitch and discuss the company's upcoming milestones. Investors will have the chance to submit questions during the event, enhancing engagement. A live webcast of the presentation will be available, along with a replay for 90 days.
Read more →AIMAIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
AIM ImmunoTech Inc. will participate in the Virtual Investor Lunch Break Series on June 5, 2024, where CEO Thomas K. Equels will give a corporate overview and business outlook. Attendees will have the opportunity to submit live questions that Mr. Equels will address during the session. The event will be accessible through a live webcast and will have a replay available shortly after the event concludes.
Read more →AIMAIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering
AIM ImmunoTech Inc. has announced a $2.0 million registered direct offering to a single institutional investor for the purchase of 5,640,958 shares of common stock at a price of $0.363 each. Concurrently, the company will issue unregistered Class A and Class B warrants for the same number of shares, each with the same exercise price. Maxim Group LLC is serving as the sole placement agent for this offering, which is expected to enhance the company's financial position without incurring excessive liabilities.
Read more →AIMAIM ImmunoTech to Participate in Two Upcoming Investor Conferences
AIM ImmunoTech Inc. announced that CEO Thomas K. Equels will present at two upcoming investor conferences. The first event is the Healthcare Company Showcase on May 21, 2024, followed by a virtual investment webinar on May 22, 2024. Both presentations will be accessible via live webcasts on the company’s website.
Read more →AIMAIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update
AIM ImmunoTech has reported its financial results for the first quarter of 2024, highlighting significant progress in its clinical development programs and positive interim data from trials. The company completed cGMP manufacturing of 9,000 vials of its lead product, Ampligen, and showed promising response rates in a study combining Ampligen with other treatments for recurrent ovarian cancer. Despite these advancements, AIM reported an increased net loss as operational costs rose, indicating continuing financial challenges.
Read more →AIMAIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast
AIM ImmunoTech Inc. has announced a conference call scheduled for May 16, 2024, to discuss its Q1 2024 financial and operational results. The call will be hosted by key management members, including the CEO and Scientific Officer. Investors and interested participants may join by phone or through a webcast available on the company's website. AIM ImmunoTech is known for its research in therapeutics for various cancers and viral diseases, including its investigational drug Ampligen®.
Read more →AIMAIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®
AIM ImmunoTech has successfully completed the cGMP manufacturing of 9,042 clinical vials of its product candidate, Ampligen (rintatolimod). This milestone is crucial for the company's development and commercial strategies as they advance their pipeline targeting various cancers and viral diseases. Ampligen is currently being evaluated in multiple clinical trials at major cancer research centers.
Read more →AIMAIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen
AIM ImmunoTech has successfully completed cGMP manufacturing of 9,042 clinical vials of its investigational drug Ampligen (rintatolimod). This achievement is significant for the company's operational strategy and is aimed at supporting both clinical trials and commercial partnerships. Ampligen is being investigated as a combinational therapy for various solid tumors in ongoing and planned clinical studies across major cancer research centers in the U.S. The company's focus on advancing its clinical pipeline is emphasized by this milestone.
Read more →AIMAIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
AIM ImmunoTech has reported that the initial dose level of its Phase 1b/2 study, combining Ampligen and Imfinzi for late-stage pancreatic cancer, is generally well-tolerated by patients. Investigators at Erasmus Medical Center confirmed that no severe adverse events or dose-limiting toxicities were encountered. Following this promising outcome, the trial will continue to its next dose escalation stage shortly. Patients will be monitored throughout their treatment course, which may last up to 48 weeks.
Read more →AIM▼ -13.7%on this newsshared move
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
AIM ImmunoTech Inc. has announced the appointment of Dr. Charles Lapp as Consulting Medical Officer to lead its development programs for Ampligen, targeting Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID. Dr. Lapp has previously been instrumental in clinical trials and will help manage new research protocols. His commitment to driving Ampligen towards FDA approval reflects optimism about the drug’s potential benefits. AIM's CEO praised Dr. Lapp’s expertise and long-standing collaboration with the team.
Read more →AIM▲ +12.9%on this news· ran to +24% by day 1shared move
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
AIM ImmunoTech announced promising interim data from its study of Ampligen combined with pembrolizumab for treating recurrent ovarian cancer. The findings suggest a more than 500% increase in the Objective Response Rate compared to existing pembrolizumab data. Additionally, the combination therapy demonstrated a median Progression-Free Survival of 7.8 months. The company plans to conduct further research and publish detailed results in a peer-reviewed journal this summer.
Read more →AIM▼ -8.2%on this news
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
AIM ImmunoTech released its fourth quarter and full year 2023 financial results, highlighting significant advancements with their lead product, Ampligen, particularly in treating various cancers and Post-COVID conditions. The company reported positive data from multiple clinical studies and has secured new patents, enhancing their position in the market. Financially, AIM's cash reserves have decreased, reflecting increased R&D and administrative expenses during the year. A conference call will discuss operational and financial results.
Read more →AIM▲ +6.3%on this newsshared move
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
AIM ImmunoTech Inc. announced that its CEO, Thomas K. Equels, will present at the MedInvest Biotech & Pharma Investor Conference on April 3, 2024. The company will also hold one-on-one meetings with registered investors. The presentation will be available via a live webcast on the company's website.
Read more →AIM▲ +6.3%on this newsshared move
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
AIM ImmunoTech Inc. announced that CEO Thomas K. Equels will present at the MedInvest Biotech & Pharma Investor Conference on April 3, 2024. Alongside the presentation, the management will engage in one-on-one meetings with select investors registered for the event. The company's focus on therapeutic advancements, particularly in immunology and oncology, highlights its commitment to addressing critical health challenges.
Read more →AIMAIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
AIM ImmunoTech Inc. will hold a conference call and webcast on April 2, 2024, to discuss its fourth quarter and full year 2023 financial results. The event will feature AIM's Chief Executive Officer and Scientific Officer, who will provide insights into the company's operational performance. The conference will be accessible via phone and online, and the webcast will be archived for 90 days. AIM ImmunoTech focuses on developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19.
Read more →AIMAIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
AIM ImmunoTech has published positive findings on Ampligen's efficacy in treating advanced pancreatic cancer. The study indicates that Ampligen enhances immune responses, correlating with improved patient outcomes. The company is exploring Ampligen's potential in combination with immune checkpoint inhibitors and is conducting ongoing clinical trials to further assess its effectiveness.
Read more →AIMAIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
AIM ImmunoTech announced the publication of positive findings regarding its drug Ampligen in a study on advanced pancreatic cancer. The study, appearing in Clinical Cancer Research, demonstrated that Ampligen enhances immune activity and correlates with improved clinical outcomes in patients. The company's CEO expressed optimism about identifying more patients who could benefit from Ampligen, while ongoing trials aim to further evaluate the drug's effectiveness in combination with immune checkpoint inhibitors. The findings suggest potential broad applicability of Ampligen in treating various solid tumors.
Read more →AIMAIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
AIM ImmunoTech Inc. is set to present at the Virtual Investor Lunch Break event on March 20, 2024. CEO Thomas K. Equels will share insights on the company's corporate overview and future opportunities. The event will be accessible via a live video webcast, with a replay available shortly after. AIM ImmunoTech focuses on developing therapeutics for cancers, immune disorders, and viral diseases, showcasing significant potential with its lead drug, Ampligen.
Read more →AIMAIM ImmunoTech Announces Launch of CEO Corner Platform
AIM ImmunoTech Inc. has announced the launch of its new CEO Corner platform, led by CEO Thomas K Equels. This initiative aims to improve communication with stakeholders by providing in-depth perspectives on press releases and corporate developments. The platform will allow interested parties to submit questions and topics for future discussions, fostering greater engagement with both current and potential stockholders. AIM emphasizes its commitment to transparency as the company continues to advance its development pipeline and grow stakeholder value.
Read more →AIMAIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
AIM ImmunoTech has reported significant progress in its clinical development pipeline for its dsRNA product candidate, Ampligen. The company has demonstrated positive results from a Phase 2 study on Post-COVID fatigue and has opened a Phase 1b/2 trial combining Ampligen with AstraZeneca's Imfinzi for pancreatic cancer. AIM is focusing on building upon its scientific successes and enhancing its business development activities. The firm aims to explore partnership opportunities to maximize the potential of Ampligen across various cancer and viral disease indications.
Read more →AIMAIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
AIM ImmunoTech has announced the dosing of the first subject in a Phase 1b/2 clinical trial at Erasmus Medical Center. The trial evaluates the combination of Ampligen® and AstraZeneca’s Imfinzi® for treating late-stage pancreatic cancer. The study aims to assess the safety and clinical benefit of this combination therapy.
Read more →AIMAIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
AIM ImmunoTech Inc. has announced the dosing of the first subject in a Phase 1b/2 clinical trial in the Netherlands, evaluating its drug Ampligen in combination with AstraZeneca's Imfinzi for treating late-stage pancreatic cancer. The DURIPANC Study aims to assess the safety and clinical benefits of this combination therapy. The trial will enroll a total of 43 subjects, focusing on the efficacy of the investigational approach to improve outcomes for patients with metastatic pancreatic ductal adenocarcinoma.
Read more →AIM▼ -12.7%on this news
AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
AIM ImmunoTech announced positive topline results from its Phase 2 study of Ampligen for treating fatigue in Post-COVID conditions. While the primary outcome did not show significant differences, secondary analyses indicated potential benefits. Ampligen was generally well tolerated, with no severe adverse events reported. The company plans further analysis to enhance future trial designs.
Read more →AIM▼ -12.7%on this newsshared move
AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions
AIM ImmunoTech has announced positive topline results from its Phase 2 study, AMP-518, which evaluated Ampligen for treating fatigue in Post-COVID conditions. The study indicated that patients receiving Ampligen experienced lower fatigue scores compared to those on placebo, although the primary measure did not achieve significant results at the 13-week mark. Safety analysis reported Ampligen as generally well tolerated, with no serious adverse events noted. The findings suggest potential efficacy and warrant further investigation in larger trials.
Read more →AIM▼ -6.9%on this news
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
AIM ImmunoTech has received ethics board authorization from Erasmus Medical Center to open a European site for its Phase 2 study of Ampligen in treating locally advanced pancreatic cancer. The AMP-270 trial will compare Ampligen's efficacy against a no-treatment control group. The study aims to enroll around 90 subjects across the U.S. and Europe.
Read more →AIM▼ -6.9%on this newsshared move
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen for the Treatment of Locally Advanced Pancreatic Cancer
AIM ImmunoTech Inc. has obtained authorization from the Erasmus Medical Center Ethics Committee to commence a European site for its Phase 2 study of Ampligen as a treatment for locally advanced pancreatic cancer. This development is a significant milestone in the AMP-270 clinical trial, which aims to enroll about 90 subjects across the United States and Europe. The study will compare the effectiveness of Ampligen to a no treatment control group following standard chemotherapy. The trial's secondary objectives will focus on assessing safety and tolerability.
Read more →AIMAIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer
AIM ImmunoTech has announced the enrollment of the first subject in its Phase 1b/2 clinical trial evaluating Ampligen in combination with AstraZeneca's Imfinzi for late-stage pancreatic cancer. The study aims to assess the safety and clinical benefit of this combination therapy. Positive outcomes could enhance AIM's attractiveness to larger pharmaceutical companies.
Read more →AIMAIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen in Combination with AstraZeneca’s Imfinzi for the Treatment of Late-Stage Pancreatic Cancer
AIM ImmunoTech has announced the enrollment of the first subject in a Phase 1b/2 clinical trial evaluating Ampligen in combination with AstraZeneca's Imfinzi for late-stage pancreatic cancer. The study, known as the DURIPANC Study, aims to assess the safety and clinical benefits of this combination therapy. The trial is expected to include up to 43 patients, and successful results may enhance AIM's value and attractiveness to larger pharmaceutical companies. The primary objectives include determining treatment safety and overall clinical benefit.
Read more →AIMAIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
AIM ImmunoTech has opened enrollment for its Phase 1b/2 clinical trial evaluating Ampligen in combination with AstraZeneca's Imfinzi for pancreatic cancer treatment. The study aims to assess safety and clinical benefit rates of the combination therapy. Researchers express optimism about the potential synergy between the two drugs, despite previous limitations in treating pancreatic ductal adenocarcinoma.
Read more →AIMAIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
AIM ImmunoTech has announced the opening of enrollment for its Phase 1b/2 clinical trial of Ampligen (rintatolimod) combined with AstraZeneca's Imfinzi (durvalumab) aimed at treating pancreatic cancer. Conducted at Erasmus Medical Center, the trial's primary focus is to assess the safety and therapeutic benefits of the combination therapy. Previous research suggests that Ampligen may enhance immune responses in pancreatic ductal adenocarcinoma, potentially leading to improved patient outcomes. The study is designed to enroll up to 43 participants across both trial phases, with dosages commencing shortly.
Read more →AIM▼ -6.4%on this newsshared move
AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting
AIM ImmunoTech Inc. announced that shareholders elected all four director nominees during its 2023 Annual Meeting. The elected directors are Stewart L. Appelrouth, Nancy K. Bryan, Thomas K. Equels, and William M. Mitchell. The company expressed gratitude to shareholders for their support and emphasized its commitment to advancing treatments for unmet patient needs. Final voting results will be certified by an independent Inspector of Elections.
Read more →AIM▼ -8.7%on this news
Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board’s Determination that Activist Group’s Nominations Are Invalid
AIM ImmunoTech has received a favorable ruling from the Delaware Court, which upheld the Board's rejection of an activist group's director nominations due to non-compliance with the company's bylaws. The court found that the activist group failed to disclose key information, validating AIM's governance practices. The company plans to reconvene its annual meeting and encourages shareholders to support its nominees.
Read more →AIM▲ +7.3%on this news
AIM ImmunoTech Provides Update Regarding Annual Meeting
AIM ImmunoTech Inc. has announced that its 2023 Annual Meeting will take place on December 1, 2023, but will be adjourned until December 29, 2023. This adjournment is to allow the Delaware Court of Chancery to rule on litigation involving an activist group seeking to nominate candidates for the Board of Directors. The AIM Board has deemed the group's nomination notice invalid due to missing and misleading information.
Read more →AIMAIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen with Issuance of Two Key U.S. Patents
AIM ImmunoTech Inc. has announced the issuance of two key U.S. patents for its drug Ampligen, enhancing its intellectual property portfolio. The patents extend exclusive rights for cancer treatment and alleviation of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) until 2039 and 2040 respectively. The patented technologies involve innovative treatment methods that may significantly improve patient outcomes in these challenging therapeutic areas. This strengthens AIM's development strategy and opens avenues for future research and partnerships.
Read more →AIMAIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
AIM ImmunoTech has announced the issuance of two significant U.S. patents for Ampligen, extending exclusive rights for cancer and ME/CFS treatments until 2039 and 2040. These patents cover novel treatment methods that could improve outcomes for patients with challenging cancers and debilitating ME/CFS symptoms. AIM's CEO emphasized the importance of these patents in strengthening the company's market position and supporting ongoing clinical studies.
Read more →AIMAIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
AIM ImmunoTech has completed treatment for the last subject in its Phase 2 study of Ampligen for post-COVID fatigue. The study involved 80 subjects and aimed to evaluate the efficacy and safety of Ampligen. No severe adverse events have been reported, and topline data is anticipated in Q1 2024.
Read more →AIMAIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions
AIM ImmunoTech has announced the completion of treatment for the last subject in its Phase 2 study, evaluating Ampligen for post-COVID conditions, specifically fatigue. Approximately 80 subjects participated in this clinical trial, which is randomized, double-blind, and placebo-controlled. No severe adverse events have been reported so far, and topline data is anticipated to be released as early as Q1 2024. The study aims to assess the efficacy and safety of Ampligen as a potential therapeutic option for individuals experiencing post-COVID fatigue.
Read more →AIMAIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update
AIM ImmunoTech Inc. has reported its financial results for the third quarter of 2023, highlighting ongoing advancements in its Ampligen® clinical programs targeting multiple cancers and post-COVID conditions. The company has encouraged data from a Phase 2 trial in ovarian cancer and maintains a strong cash position expected to support its operations into 2024. Furthermore, AIM's partnership efforts and details regarding imminent milestones in clinical trials underline its strategic forward momentum. However, the company also noted an increase in operational losses compared to the same period last year.
Read more →AIMAIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer
AIM ImmunoTech Inc. announced the publication of results from a Phase 1 study at Roswell Park Comprehensive Cancer Center, evaluating Ampligen as part of a chemokine-modulating regimen for metastatic triple-negative breast cancer (mTNBC). The study, which included other agents such as interferon α-2b and celecoxib, focused on the therapy's safety and its ability to enhance local cytotoxic T lymphocyte influx into mTNBC lesions. Principal investigator Dr. Shipra Gandhi led the study, and the results were published in a notable journal, highlighting the potential of this therapeutic combination. The findings contribute to ongoing research efforts in oncology aimed at improving treatment modalities for challenging cancer types.
Read more →AIM▼ -8.1%on this newsshared move
AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast
AIM ImmunoTech Inc. has announced that its management will host a conference call and webcast on November 15, 2023, to discuss third quarter 2023 operational and financial results. The call will feature AIM's CEO Thomas K. Equels and Scientific Officer Christopher McAleer. Participants can join the call either by phone or through a webcast on the company’s website. AIM ImmunoTech is focused on developing therapeutics for cancer, immune disorders, and viral diseases.
Read more →AIMAIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian Cancer
AIM ImmunoTech announced positive translational data from its ongoing Phase 2 study of Ampligen for advanced recurrent ovarian cancer. The study, presented at the SITC 38th Annual Meeting, highlighted significant immune responses and cellular changes in the tumor microenvironment. Topline interim results are expected by year-end, indicating potential for improved patient outcomes.
Read more →AIMAIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen for the Treatment of Advanced Recurrent Ovarian Cancer
AIM ImmunoTech has announced promising data from its ongoing Phase 2 clinical trial assessing the efficacy of its drug Ampligen in treating platinum-sensitive advanced recurrent ovarian cancer. The findings indicate a gradual and sustainable immune response over time, particularly in T lymphotactic CXCR3 ligands and cytolytic factors. Experts have highlighted the improved activation of T-cell cytotoxicity with this combination therapy, which shows potential for better clinical outcomes. Topline interim results are expected before the end of the year, further underscoring the advancement of this research.
Read more →AIM▲ +7%on this news· ran to +19% by day 3
AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
AIM ImmunoTech Inc. announced that an abstract from the Magee-Womens Research Institute has been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. The research focuses on a Phase 2 trial evaluating the combination of intensive locoregional chemoimmunotherapy with AIM's drug Ampligen and pembrolizumab for patients with recurrent platinum-sensitive ovarian cancer. This presentation will take place from November 1-5, 2023, in San Diego, CA.
Read more →AIM▲ +10.4%on this news
AIM ImmunoTech Engages Business Development Firm, Azenova, LLC to Catalyze Partnering, Development and Commercialization Efforts for Ampligen® Pipeline Programs
AIM ImmunoTech has partnered with Azenova, LLC to enhance business development for its lead asset, Ampligen®, aimed at treating malignant solid tumors. This collaboration seeks to secure partnerships or licensing agreements to further develop and commercialize Ampligen®. AIM's CEO expressed confidence in Ampligen's potential based on promising clinical data, although no transaction is guaranteed.
Read more →AIM▲ +10.4%on this newsshared move
AIM ImmunoTech Engages Business Development Firm, Azenova, LLC to Catalyze Partnering, Development and Commercialization Efforts for Ampligen Pipeline Programs
AIM ImmunoTech Inc. has engaged Azenova, LLC to enhance its business development efforts for its lead asset, Ampligen, which is aimed at treating malignant solid tumors. This partnership intends to explore potential licensing or partnerships to further develop and commercialize Ampligen. Although the management is optimistic about the drug's therapeutic potential based on clinical data, there is no guarantee that this engagement will result in successful transactions. Azenova will provide strategic support to maximize opportunities for AIM's pipeline programs.
Read more →AIMAIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
AIM ImmunoTech Inc. has announced that Dr. Chris McAleer will present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care held at Roswell Park Comprehensive Cancer Center from September 20-22, 2023. The presentation will cover the clinical progress of Rintatolimod (Ampligen) in oncology. Additionally, AIM is proud to sponsor the event, highlighting its dedication to advancements in cancer research.
Read more →AIM▲ +8%on this news
AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer
AIM ImmunoTech announced the release of complete topline data from a Phase 1 study conducted at Roswell Park Comprehensive Cancer Center. The study evaluated the safety and tolerability of Ampligen in combination with a CKM regimen for treating early-stage triple negative breast cancer. Results indicated a promising clinical response rate of 66% and that the treatment was well tolerated. A Phase 2 study is planned to further investigate Ampligen's viability as a treatment option for patients with this cancer type.
Read more →AIMAIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference
AIM ImmunoTech Inc. has announced that its CEO, Thomas K. Equels, will present at the H.C. Wainwright 25th Annual Global Investment Conference taking place from September 11-13, 2023. During the event, management will also engage in virtual one-on-one meetings with registered investors. A video webcast of the presentation will be available on-demand starting September 11, with an archive period of 90 days following the event. AIM is focused on developing immunotherapy treatments for cancers, immune disorders, and viral diseases.
Read more →AIMAIM ImmunoTech Rejects Director Nomination Notice from Activist Group Due to Numerous Material Defects, Omissions and False and Misleading Statements
AIM ImmunoTech has rejected a director nomination notice from an activist group, citing numerous material defects and misleading statements. The group, which previously attempted to take control of the Board in 2022, failed to comply with AIM's bylaws. AIM's Board concluded that the notice was invalid and will not recognize the nominations, aiming to protect shareholder interests.
Read more →AIMNorth Market Street P.O. Box 951 Wilmington, DE 19801- 0951 302 984 6000 www.potteranderson.com Michael A. Pittenger mpittenger@potteranderson.com 302 984-6136 Direct Phone 302 778-6136 Fax
AIM ImmunoTech Inc. is responding to a purported notice from Ted D. Kellner, who intends to nominate himself and two others to the board during the upcoming 2023 Annual Meeting. The company claims that Kellner's notice does not meet the criteria set forth in its Advance Notice Bylaw, citing inaccuracies and omissions in the details required for nominations. This situation follows prior nomination disputes that have led to court involvement, highlighting ongoing governance challenges within the company.
Read more →AIM▼ -6.3%on this news
AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update
AIM ImmunoTech has reported its second-quarter financial results, showing continued operational execution towards clinical and regulatory milestones. The company remains optimistic about its lead product Ampligen, highlighting significant progress in clinical studies, especially concerning pancreatic cancer treatment. Notably, recent data from the Early Access Program indicates improved survival rates for patients receiving Ampligen. AIM is well-positioned with a robust cash position, planning to fund operations through 2024 as it approaches several critical milestone events.
Read more →AIMAIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast
AIM ImmunoTech Inc. will announce its Q2 2023 operational and financial results during a conference call and webcast on August 15, 2023. The event will feature the company's leadership, including CEO Thomas K. Equels and Scientific Officer Christopher McAleer, providing insights into the company's performance. Participants can join the call or access it via the company's website, where it will be archived for 90 days. AIM ImmunoTech focuses on developing therapies for cancers, immune disorders, and viral diseases, including COVID-19.
Read more →AIMAIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
AIM ImmunoTech has completed enrollment in its Phase 2 study evaluating Ampligen® for post-COVID conditions, with 80 subjects participating. The study aims to assess the drug's efficacy and safety, with results anticipated in early 2024. The rapid enrollment reflects the urgent need for therapeutic options for Long COVID patients.
Read more →AIMAIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions
AIM ImmunoTech has completed enrollment in its Phase 2 AMP-518 study evaluating Ampligen for post-COVID conditions, specifically targeting chronic fatigue-like symptoms. The study enrolled 80 subjects aged 18 to 60, who will receive either Ampligen or placebo for 12 weeks, followed by a two-week monitoring phase. AIM expects to complete patient dosing by Q4 2023, with initial results projected for Q1 2024. This milestone underscores the urgent medical need for effective treatments for Long COVID.
Read more →AIM▲ +8.4%on this news
AIM ImmunoTech Issues Notice that an Unaffiliated Third Party and Organization are Providing False Information Related to Relationship with Company and its Affiliates
AIM ImmunoTech has issued a notice regarding unauthorized third parties misrepresenting the company on LinkedIn. These individuals are claiming to represent AIM ImmunoTech Europe and have disseminated false information about AIM's clinical activities, particularly related to pancreatic cancer. AIM denies any association with these unauthorized profiles and is actively working to eliminate this misinformation. This situation poses risks to the company's reputation and may mislead stakeholders.
Read more →AIMAIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
AIM ImmunoTech has initiated a Phase 2 study, AMP-518, to evaluate Ampligen as a treatment for post-COVID conditions. The first subject has been dosed, with enrollment expected to complete by Q4 2023. The study aims to assess the efficacy and safety of Ampligen in addressing chronic fatigue symptoms associated with Long COVID. The trial will include approximately 80 subjects across multiple centers in the U.S.
Read more →AIMAIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions
AIM ImmunoTech has announced the enrollment and dosing of the first subject in its Phase 2 study of Ampligen for treating post-COVID conditions. The study aims to address the significant unmet medical need, particularly for patients experiencing chronic fatigue post-COVID. With a planned enrollment of around 80 subjects, the trial will evaluate the efficacy and safety of Ampligen in a randomized, double-blind, placebo-controlled setting. Challenges remain, including the need for extensive testing to confirm Ampligen's effectiveness.
Read more →AIMAIM ImmunoTech to Participate in the Virtual Investor Summer Spotlight Series
AIM ImmunoTech Inc. has announced its participation in the Virtual Investor Summer Spotlight Series on July 12, 2023. CEO Thomas K. Equels and Scientific Officer Dr. Christopher McAleer will present during the event. A live video webcast of the presentation will be available on the company’s website, along with a replay accessible for 90 days. AIM ImmunoTech specializes in developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19.
Read more →AIM▲ +7%on this news· ran to +27% by day 3
AIM ImmunoTech Announces Publication of Positive Findings from a Pre-Clinical Study Evaluating Ampligen in the Treatment of Pancreatic Cancer in the American Journal of Cancer Research
AIM ImmunoTech Inc. announced the publication of positive findings from a pre-clinical study evaluating its immune-modulating drug, Ampligen, for treating pancreatic cancer. The study, published in the American Journal of Cancer Research, suggests that Ampligen can reduce tumor cell growth in patients with sufficient TLR-3 expression. These findings support the potential of TLR-3 as a biomarker for identifying responsive patients. AIM is focused on furthering research and clinical trials to establish Ampligen as a standard treatment option for pancreatic cancer.
Read more →AIM▲ +7%on this news· ran to +27% by day 3
AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin a Phase 1b/2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
AIM ImmunoTech announced that it received authorizations from the Competent Authority and Ethics Board in the Netherlands to commence a Phase 1b/2 study of Ampligen in combination with AstraZeneca's durvalumab for treating pancreatic cancer. The study aims to assess both the safety and clinical benefits of this drug combination in patients with advanced pancreatic cancer. Enrollment is anticipated to begin before the end of 2023, marking a significant step in AIM's research and development efforts.
Read more →AIMAIM ImmunoTech to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
AIM ImmunoTech Inc. will present at the Healthcare Virtual Conference Part II on June 21, 2023. The conference, hosted by M-Vest and presented by Maxim Group LLC, aims to engage various biotechnology and medical device companies in discussions about innovative therapeutics. CEO Thomas K Equels will lead the presentation, highlighting AIM’s commitment to addressing multiple types of cancers and viral diseases through its investigational drug Ampligen®. The event signifies an opportunity for AIM to enhance its visibility in the healthcare sector.
Read more →AIMAIM ImmunoTech Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments
AIM ImmunoTech has announced notable advancements in its clinical development pipeline, particularly concerning its lead product, Ampligen. The company is now actively recruiting participants for Phase 2 trials aimed at treating locally advanced pancreatic cancer, along with ongoing studies for early-stage triple negative breast cancer. Recent analyses suggest potential biomarkers that may help identify patients likely to respond favorably to Ampligen, reinforcing its therapeutic promise. Additionally, AIM has secured a new patent for Ampligen as a possible treatment for Ebola virus disease, further expanding its applications.
Read more →AIMAIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline Update
AIM ImmunoTech Inc. recently reported its first quarter financial results and showcased progress in its clinical pipeline. The company is poised to enroll its first patient in a Phase 2 study for advanced pancreatic cancer and expects to provide interim results for advanced recurrent ovarian cancer in Q3 2023. Despite a net loss of $3.7 million for the quarter, AIM maintains a strong cash position with $30.8 million on hand, aiming to navigate through key milestones into 2024.
Read more →AIMAIM ImmunoTech to Discuss First Quarter 2023 Financial Results on May 16, 2023 and Host Conference Call and Webcast
AIM ImmunoTech Inc. is set to host a conference call and webcast on May 16, 2023, to discuss its first quarter 2023 operational and financial results. The call will feature AIM's CEO, Thomas K. Equels, and Scientific Officer, Christopher McAleer. AIM ImmunoTech specializes in the development of therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19, with its lead product being the investigational drug Ampligen®.
Read more →AIM▲ +9.2%on this news
AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB)
AIM ImmunoTech Inc. has announced the appointment of Dr. W. Neal Burnette as the Chairman of its Scientific Advisory Board. Dr. Burnette brings significant experience from his extensive background in biomedical research and contributions to vaccine development. His leadership is expected to strengthen AIM's efforts in advancing its pipeline focused on treating cancers, immune disorders, and viral diseases. The existing members of the SAB also possess diverse expertise that could enhance AIM's research initiatives.
Read more →AIM▲ +6.1%on this news
AIM ImmunoTech Announces Central IRB Approval of Phase 2 Study Protocol Evaluating Ampligen for the Treatment of Post-COVID Conditions
AIM ImmunoTech has received central IRB approval for its Phase 2 clinical trial protocol evaluating Ampligen for patients suffering from post-COVID conditions, specifically chronic fatigue. The AMP-518 trial will investigate the efficacy and safety of Ampligen in a randomized, double-blind study design involving approximately 80 subjects. The company anticipates beginning patient enrollment and dosing in the second quarter of 2023, reinforcing its commitment to addressing this growing medical need.
Read more →AIMAIM ImmunoTech Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
AIM ImmunoTech reported its financial results for the fourth quarter and full year 2022, highlighting a strong pipeline with 12 active clinical programs. The company achieved significant progress in its development of Ampligen, particularly for cancers and viral diseases. AIM's commitment to advance immunology solutions includes plans to host an inaugural conference call to discuss these developments. Additionally, the company is making strides in expanding its patent portfolio and has appointed new leadership to facilitate growth.
Read more →AIMAIM ImmunoTech Bolsters Board of Directors with Appointment of Pharmaceutical Industry Veteran Nancy K. Bryan, with Deep Commercial, Marketing, Business Development and Corporate Finance Expertise
AIM ImmunoTech Inc. has appointed Nancy K. Bryan, a seasoned pharmaceutical executive, to its Board of Directors. With over 25 years in the life sciences industry, Bryan brings valuable experience in marketing, business development, and corporate finance. She aims to leverage her expertise as AIM progresses its lead product, Ampligen, towards late-stage development. This appointment also underscores AIM's commitment to fostering diversity on its board.
Read more →AIM▼ -5.1%on this newsshared move
AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast
AIM ImmunoTech Inc. has announced that it will report its financial results for the full year ended December 31, 2022, after market close on March 31, 2023. Following this announcement, the company will host its inaugural quarterly conference call on April 3, 2023, at 8:30 AM ET, to discuss operational and financial results. AIM is actively involved in developing therapeutics for various health challenges, including cancer and COVID-19.
Read more →AIMCONFIDENTIAL DRAFT NOT FOR IMMEDIATE RELEASE AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease
AIM ImmunoTech announced a late-breaking presentation at the International Conference on Antiviral Research, detailing Ampligen's potential as a therapy against Ebola Virus Disease. The presentation highlighted that Ampligen could act as both a prophylactic and an early therapeutic option, showcasing 100% protective outcomes in pre-clinical animal studies. However, the drug is not currently approved for these uses, and further testing will be necessary to evaluate its efficacy in humans. AIM aims to file Investigational New Drug applications for Ampligen's use in treating EBOV and preventing reactivation.
Read more →AIMAIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease
AIM ImmunoTech announced a late-breaking presentation on Ampligen at the International Conference on Antiviral Research, highlighting its mechanism of action against Ebola virus disease (EVD). The presented data showed that Ampligen acts as a TLR3 agonist, enhancing immune responses and demonstrating protective effects in preclinical studies. The company intends to pursue Investigational New Drug applications for both early treatment and prevention of EVD, although Ampligen is not currently approved for these uses.
Read more →AIMAIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease
AIM ImmunoTech announced new findings supporting its drug Ampligen as a potential prophylactic therapy against Ebola virus disease (EVD). The study, published in Antiviral Research, details Ampligen's ability to elicit immune responses and inhibit the virus’s lethal factor. Although Ampligen has shown promising results in animal models, it is not yet approved for human use, and the company plans to seek regulatory approvals and develop its applications further.
Read more →AIMAIM ImmunoTech Issues Letter to Stockholders
AIM ImmunoTech has issued a letter to stockholders detailing its achievements in 2022 and objectives for 2023. The company highlighted notable progress in its oncology programs and plans to initiate several clinical studies in the upcoming year. AIM's dedication to transparency and engagement with the investment community is emphasized, as it prepares for a busy year ahead with multiple expected milestones. The letter also celebrates the successful execution of clinical trials and the strategic appointment of new leadership.
Read more →AIMAIM ImmunoTech Issues Letter to Stockholders Year marked by noteworthy operational execution and clinical development progress across pipeline Company reiterates commitment to continued communication and activity with th
AIM ImmunoTech issued a letter to stockholders detailing its operational successes in 2022 and outlining its objectives for 2023. The company achieved key milestones, including IND clearances and positive clinical data across various programs. AIM emphasizes its commitment to communication with stakeholders and plans to initiate numerous clinical trials this year, positioning itself well for future growth in the immuno-pharma space.
Read more →AIM▲ +8.4%on this news
AIM ImmunoTech Announces Phase 2 Study of Ampligen for the Treatment of Pancreatic Cancer is Open and Recruiting Patients
AIM ImmunoTech has initiated the AMP-270 Phase 2 clinical trial for Ampligen as a treatment for locally advanced pancreatic cancer, opening its first site in Ohio. The study aims to compare Ampligen's efficacy against a no-treatment control group after standard chemotherapy with FOLFIRINOX. Comprising approximately 90 subjects across up to 30 centers, the trial addresses an unmet medical need in this aggressive cancer type. AIM anticipates expanding its patient recruitment through partnerships with leading cancer research institutions.
Read more →AIM▲ +6.4%on this news
AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, “Long Covid: What Will It Take To Accelerate Therapeutic Progress?”
AIM ImmunoTech Inc. announced its participation in a virtual event hosted by Solve M.E. and BIO, aimed at advancing research and therapeutic strategies for Long Covid and ME/CFS. During the event, CEO Thomas K. Equels will present clinical development plans for Ampligen (rintatolimod), which has shown preliminary success in reducing fatigue in Long Covid patients. The FDA has cleared a Phase 2 study for Ampligen, although previous data is based on a limited sample size and further testing is necessary to confirm effectiveness.
Read more →AIM▲ +22.5%on this news
CONFIDENTIAL DRAFT NOT FOR IMMEDIATE RELEASE AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center Research collaboration will evaluate the potential of AIM
AIM ImmunoTech has announced a clinical research collaboration with AstraZeneca and Erasmus Medical Center to evaluate the potential of its drug Ampligen in combination with AstraZeneca's Imfinzi for treating pancreatic cancer. The study will explore how this combination may enhance immune system responses against pancreatic ductal adenocarcinoma, which presents a significant treatment challenge. Previous studies suggest that Ampligen could help improve outcomes in patients through its effects on T-cell activation. This effort seeks to address the significant unmet medical need in treating pancreatic cancer.
Read more →AIM▲ +22.5%on this news
AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center
AIM ImmunoTech has announced a collaborative agreement with AstraZeneca and Erasmus Medical Center to conduct clinical research on pancreatic cancer. The study will investigate the combined use of the PD-L1 inhibitor durvalumab and AIM's drug Ampligen in patients with metastatic pancreatic ductal adenocarcinoma. Previous data suggests that Ampligen may enhance the effectiveness of checkpoint inhibitors by activating the immune response. This collaboration aims to address the significant unmet needs in pancreatic cancer treatment.
Read more →AIMAIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention
AIM ImmunoTech has announced the granting of a new utility patent by the Netherlands Patent Office, which covers rugged dsRNA products for COVID-19 treatment and prevention. This patent broadens the company's existing intellectual property related to Ampligen, its RNA product candidate. Ampligen has shown promising antiviral activity through various studies against SARS-CoV-2, indicating its potential in modulating immune responses and treating viral diseases. AIM continues to develop Ampligen for various uses, including as a therapy for pancreatic cancer and chronic fatigue syndrome.
Read more →AIM▲ +13.5%on this news· ran to +29% by day 3shared move
AIM ImmunoTech to Present at the ‘Virtual Investor 2023 Companies to Watch Event’
AIM ImmunoTech Inc. announced that its CEO will present at the Virtual Investor 2023 Companies to Watch Event on January 18, 2023. The company focuses on developing therapeutics for cancers, immune disorders, and viral diseases, particularly its lead product, Ampligen. This product is currently involved in clinical trials for pancreatic cancer and has received approval for the treatment of severe chronic fatigue syndrome in Argentina. AIM continues to progress with several clinical studies to expand Ampligen's therapeutic applications.
Read more →AIMAIM ImmunoTech Appoints Christopher McAleer, Ph.D. as Scientific Officer
OCALA, Fla., Dec. 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including C
Read more →AIMAIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen (Rintatolimod) in Healthy Subjects
Intranasal administration of Ampligen demonstrated to be well-tolerated Based on data generated to date, Ampligen could have potential as a prophylactic or early treatment against respiratory viral infections Data presented in poster presentation at the British Society for Immu
Read more →AIMAIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022
OCALA, Fla., Dec. 02, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including
Read more →AIMAIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update
– Company continues to execute and is well-positioned to achieve multiple near-term clinical and regulatory value-driving milestones – Cash position expected to fund operations through end of 2023 OCALA, Fla., Nov. 15, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American
Read more →AIM▼ -6.8%on this newsshared move
AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer
– Data selected for poster presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting – Treatment was well tolerated, with promising clinical activity of pathologic complete response (pCR) + microinvasive residual disease (ypTmic) at 66%, comparable to pe
Read more →AIMAIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus Disease
Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity currently being evaluated for the treatment of globally important cancers, viral diseases and disorders of the immune system Ampligen has demonstrated positive results for the treatment of Ebola in prev
Read more →AIM▼ -7.9%on this news
AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions
OCALA, Fla., Oct. 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including C
Read more →AIMAIM ImmunoTech to Present at the Virtual Investor Long COVID Event
OCALA, Fla., Sept. 21, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including
Read more →AIMAIM ImmunoTech to Present at the H.C. Wainwright 24th Annual Global Investment Conference
OCALA, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including
Read more →AIMAIM ImmunoTech Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
OCALA, Fla., Sept. 06, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including
Read more →AIMAIM ImmunoTech and Study Collaborator Roswell Park Commence Enrollment in an NCI-funded Phase 2 Clinical Trial Evaluating Ampligen (rintatolimod) in Primary PD-1/PD-L1 Resistant Melanoma
Phase 2 to evaluate polarized dendritic cell vaccine, interferon alpha-2b, Ampligen and celecoxib for the treatment of HLA-A2+ refractory melanoma First patient dosing is expected in Q4, 2022 OCALA, Fla., Aug. 30, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM
Read more →AIMAIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen for the Treatment of Pancreatic Cancer
Company receives IRB approval of study protocol Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with locally advanced pancreatic cancer OCALA, Fla., Aug. 18, 2022 (GLOBE NEWSWIRE) -- AIM Imm
Read more →AIMAIM ImmunoTech Reports Second Quarter 2022 Financial Results and Provides Corporate Update
– On track to commence Phase 2 study for lead program evaluating Ampligen® (rintatolimod) for the treatment of pancreatic cancer in Q3 2022 – Well-positioned to achieve multiple near-term clinical and regulatory value-driving milestones – Capital position expected to fund compa
Read more →AIMAIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen for the Treatment of Long COVID
OCALA, Fla., July 28, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including
Read more →AIM▲ +11.1%on this news
AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data
Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and locally advanced pancreatic cancer (LAPC) New patient data provide further validation for advancing the development of Ampl
Read more →AIMAIM ImmunoTech Announces that Recently Received Director Nominations from Jorgl Activist Group are Invalid
Files Complaint in Federal Court to Compel Activist Group to Reveal True Intentions – Including a Potential Hostile Takeover of the Company – and Prevent Group from Continued Violations of Federal Securities Laws and SEC and Florida Injunctions Complaint Highlights Certain Activ
Read more →AIMAIM ImmunoTech to Present at the Virtual Investor Innovations in Oncology Spotlight Series
OCALA, Fla., July 14, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including C
Read more →AIMAIM ImmunoTech Secures New State-of-the-Art Facility for Product Development and Testing
OCALA, Fla., June 21, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including C
Read more →AIM▼ -6.8%on this news
AIM ImmunoTech Bolsters Intellectual Property Portfolio for Ampligen with Issuance of New Netherlands Utility Patent Covering Ampligen and other AIM Developed dsRNA Products for Use in COVID-19 Treatment or Prevention
OCALA, Fla., June 13, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including C
Read more →AIM▲ +5.4%on this news
AIM ImmunoTech to Present at the H.C. Wainwright Global Investment Conference
OCALA, Fla., May 19, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including CO
Read more →AIM▼ -6.2%on this newsshared move
AIM ImmunoTech Provides Update on Ampligen Long COVID Development Program
OCALA, Fla., May 18, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including CO
Read more →AIMAIM ImmunoTech Reports First Quarter 2022 Financial Results and Provides Corporate Update
- First quarter marked by peer-reviewed journal and abstract publications showcasing statistically significant efficacy data of Ampligen in late-stage pancreatic cancer; results also showcased continued positive data in ovarian and triple-negative breast cancer clinical studies a
Read more →AIMAIM ImmunoTech to Participate in a Solve M.E. Signature Event: ‘Long COVID: Research, Policy, and Economic Impact’ on May 19, 2022
OCALA, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including CO
Read more →AIMAIM ImmunoTech Provides Summary of Ampligen Data Supporting Synergistic Potential with Checkpoint Blockade Therapies
Ampligen has demonstrated in pre-clinical and now human clinical studies a potential to enhance efficacy of PD-1 and/or PD-L1 checkpoint inhibitors Ampligen’s anti-tumor potential is demonstrated with checkpoint blockade therapies in human clinical studies for the treatment of t
Read more →AIM▼ -25.2%on this news
AIM ImmunoTech Provides Progress on Advancement of Ampligen Clinical Development Program for the Treatment of Pancreatic Cancer
- Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with advanced pancreatic cancer - Company engages world-renowned CRO, Amarex Clinical Research LLC to conduct upcoming Phase 2 study - Compa
Read more →AIM▲ +17.6%on this newsshared move
AIM ImmunoTech Announces Positive Data from Phase 2a Study Evaluating Ampligen as a Component of a Chemokine Modulatory (CKM) Regimen for the Treatment of Colorectal Cancer Metastatic to the Liver
Primary endpoint of the study was met, evidenced by increased CD8a expression post-treatment (p=0.046) Data suggest that CKM regimen with Ampligen may be useful to enhance effectiveness of immunotherapies Data from clinical research conducted at Roswell Park Comprehensive Cance
Read more →AIMAIM ImmunoTech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
- Year marked by continued execution across clinical development programs and the continued establishment of a growing body of positive data with Ampligen® in multiple high-value indications - Company expected to continue advancing oncology-focused pipeline and well positioned t
Read more →AIMAIM ImmunoTech Announces Abstract Accepted for Presentation at 15th Annual IHPBA World Congress
OCALA, Fla., March 28, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including
Read more →AIMAIM ImmunoTech to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
OCALA, Fla., March 23, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including
Read more →AIM▲ +14.7%on this news· ran to +44% by day 3
AIM ImmunoTech Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Ampligen for the Treatment of Locally Advanced Pancreatic Cancer
Data seen to date indicates that Ampligen® (rintatolimod) could be a potential effective maintenance therapy after systemic chemotherapy in patients with advanced pancreatic cancer In a single-center named patient program, treatment with Ampligen following FOLFIRINOX was associa
Read more →AIM▲ +14.2%on this news
AIM ImmunoTech Announces Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the AACR 2022 Annual Meeting
OCALA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including
Read more →AIM▲ +14.2%on this news
AIM ImmunoTech Announces Abstracts from Roswell Park Comprehensive Cancer Center Accepted for Presentation in a Late-Breaking Poster Session at the AACR 2022 Annual Meeting
OCALA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including
Read more →AIM▲ +9.5%on this news· ran to +25% by day 1shared move
AIM ImmunoTech Announces Publication of Positive Data from Late-Stage Pancreatic Cancer Early Access Program (EAP) in the Cancers Special Issue: Combination and Innovative Therapies for Pancreatic Cancer
Ampligen® (rintatolimod) is being evaluated as a monotherapy to treat pancreatic cancer patients in an Early Access Program (EAP) approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center Treatment with Ampligen following FOLFIRINOX was associated w
Read more →AIMAIM ImmunoTech Announces Strategic Sale of New Brunswick, New Jersey Facility to Allocate Additional Resources to Advance Pipeline
OCALA, Fla., March 07, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including
Read more →AIMAIM ImmunoTech Appoints Robert Dickey, IV as Chief Financial Officer
OCALA, Fla., March 03, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including
Read more →AIMAIM ImmunoTech to Participate in a Solve M.E. Diagnostics and Treatments Webinar
AIM ImmunoTech management to participate in webinar Thursday, January 27th from 2:00 pm - 3:00 pm ET Company to discuss clinical plans for investigational drug Ampligen for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID OCALA, Fla.,
Read more →AIM▼ -6.7%on this newsshared move
AIM ImmunoTech Announces Publication of Positive Results from Phase 1/2 Study of Intraperitoneal Chemo-Immunotherapy in Advanced Recurrent Ovarian Cancer
Chemokine-modulating IP chemo-immunotherapy combination demonstrated to be well tolerated, and associated with interferon stimulated gene changes that favor cytotoxic T lymphocytes chemoattraction and function Strength of data support advancement into Phase 2 clinical study Pha
Read more →AIM▼ -9.1%on this newsshared move
AIM ImmunoTech to Present at the Virtual Investor 2022 Top Picks Conference
OCALA, Fla., Jan. 19, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including C
Read more →AIM▼ -11.2%on this news· ran to -24% by day 3
AIM ImmunoTech’s Ampligen Safety Data Presented at Eighth European Scientific Working Group on Influenza
OCALA, Fla., Dec. 09, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that safety data on its drug Ampligen was recently presented at the Eighth European Scientific Working Group on Influenza (ESWI) virtual conference in Salzburg, Austria, on Dec
Read more →AIMAIM ImmunoTech CEO to Participate in Two Upcoming Investor Conferences
OCALA, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas Equels, Chief Executive Officer of AIM, will be participating in two upcoming investor conferences. BioFlorida Conference Mr. Equels will be participating in the
Read more →AIMAIM ImmunoTech Provides Third Quarter 2021 Business Update
OCALA, Fla., Nov. 16, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the third quarter ended September 30, 2021 and provides a business update. Third Quarter 2021 Financial Highlights: As of September 30, 2021, AIM had cash, ca
Read more →AIMAIM ImmunoTech Submits IND and Accompanying Fast Track Application for Phase 2 Trial of Ampligen in Patients with Locally Advanced or Metastatic Late-Stage Pancreatic Cancer
OCALA, Fla., Oct. 19, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has submitted an Investigational New Drug application (IND) and an accompanying application for Fast Track status with the U.S. Food and Drug Administration (FDA) for a
Read more →AIMAIM ImmunoTech Publishes Phase 1 Clinical Study Data Supporting the Safety of Ampligen as an Intranasal Therapy
OCALA, Fla., Oct. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today released detailed safety data from a Phase 1 clinical study which supports the company’s belief that its drug Ampligen has significant potential as an intranasal therapeutic for COVID-19
Read more →AIMAIM ImmunoTech Provides Clinical Updates on Planned Phase 2 Study of Ampligen in Patients with Locally Advanced or Metastatic Late-Stage Pancreatic Cancer
Finalizes and reports Phase 2 study protocol Expects to submit IND and apply for Fast Track Status with the FDA by October 18, 2021 Selects the Buffett Cancer Center and Erasmus MC as primary study sites OCALA, Fla., Oct. 04, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE
Read more →AIMAIM ImmunoTech Announces Clinical Trial Agreement for a Phase 2a Human Challenge Trial of Ampligen as a Potential Intranasal Prophylaxis Against Respiratory Viruses
OCALA, Fla., Sept. 30, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American:AIM) today announced that AIM and hVIVO have a signed Clinical Trial Agreement (CTA) for a Phase 2a Human Challenge Trial (HCT) to test the company’s drug Ampligen as a potential intranasal prophyl
Read more →AIMAIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Studies of Ampligen as a Potential Early-Onset Therapeutic for COVID-19
OCALA, Fla., Sept. 28, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that is has submitted a Pre-Investigational New Drug application (Pre-IND) to the U.S. Food and Drug Administration (FDA) for two separate Phase 2 clinical studies to study th
Read more →AIMAIM ImmunoTech Files Provisional Patent Application for Ampligen as an Early-Onset Intranasal Therapy that May Also Confer Enhanced Immunity to a Wide Range of Respiratory Viruses
OCALA, Fla., Sept. 27, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced the filing of a provisional patent application for Ampligen as a potential early-onset intranasal therapy designed to enhance and expand infection-induced immunity, epitope sp
Read more →AIMAIM ImmunoTech Announces Positive Progress on Requested FDA Meeting for Proposed Ampligen Clinical Trial in Post-COVID-19 Cognitive Dysfunction
OCALA, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced positive progress with the company’s meeting request to the U.S. Food and Drug Administration (FDA) concerning a Phase 2 clinical study of Ampligen as an infusion therapy for
Read more →AIMAIM ImmunoTech Provides an Update on Its Pending Phase 2a Human Challenge Trial Using its Drug Ampligen
OCALA, Fla., Sept. 20, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today provided a status update on its Phase 2a Human Challenge Trial (HCT) to test the company’s drug Ampligen as a potential intranasal prophylactic therapy using a human rhinovirus (HRV-16,
Read more →AIMAIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Study of Ampligen as a Potential Infusion Therapy for Post-COVID-19 Cognitive Dysfunction
OCALA, Fla., Sept. 08, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that is has submitted a Pre-Investigational New Drug application (Pre-IND) to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of Ampligen as a potenti
Read more →AIMAIM ImmunoTech Announces Filing of Provisional Patent Application for Use of Ampligen as Both an Intranasal and an IV Therapy for Post-COVID-19 Cognitive Dysfunction (PCCD)
OCALA, Fla., Aug. 25, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today provided an update on the company’s efforts to develop its drug Ampligen as a potential intranasal therapeutic for COVID-19, including the announcement of a new provisional patent applic
Read more →AIMAIM ImmunoTech Provides Second Quarter 2021 Business Update
OCALA, Fla., Aug. 17, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the second quarter ended June 30, 2021 and provides a business update. Second Quarter 2021 Financial Highlights: As of June 30, 2021, AIM had cash, cash equiv
Read more →AIMAIM ImmunoTech Announces Phase 2a Human Challenge Trial to Test its Drug Ampligen as an Intranasal Antiviral Prophylactic Therapy
OCALA, Fla., July 09, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test the company’s drug Ampligen as a potential intranasal antiviral therapy using a human Rh
Read more →AIMAIM ImmunoTech to Host Investor Update Webcast on Wednesday, July 14th at 11:00 AM ET
OCALA, Fla., July 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it will host an investor update webcast at 11:00 a.m. Eastern Time on Wednesday, July 14, 2021, to discuss recent accomplishments and upcoming milestones. Investors and ot
Read more →AIMAIM ImmunoTech Completes All Treatments in Phase 1 Human Safety Study of Intranasal Administration of Ampligen
OCALA, Fla., June 21, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that all subjects have completed treatment in the Company’s Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as a potential intrana
Read more →AIMAIM ImmunoTech’s Ampligen Featured in Peer-Reviewed Journal Cancers as a Potential Therapy for Cancer Patients with SARS-CoV-2
OCALA, Fla., June 14, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that its drug Ampligen has been featured in a publication containing state-of-the-art methodologies in the peer-reviewed medical journal Cancers as a potential treatment option
Read more →AIMAIM ImmunoTech Announces Two Year Extension of Agreement with Shenzhen Smoore Technology Limited to Develop and Test a New Inhalation Delivery Device for Ampligen
OCALA, Fla., May 27, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has entered into a two-year extension of its Material Transfer and Research Agreement with Shenzhen Smoore Technology Limited (Smoore), a subsidiary of Smoore Internatio
Read more →AIMAIM ImmunoTech Announces Positive Safety Data from the Third Cohort of Its Phase 1 Intranasal Clinical Trial
OCALA, Fla., May 26, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 3 in a Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as an intranasal therapy, reporting n
Read more →AIMAIM ImmunoTech Provides First Quarter 2021 Business Update
OCALA, Fla., May 18, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the first quarter ended March 31, 2021. As of March 31, 2021, AIM had cash, cash equivalents and marketable securities of $63.6 million, compared to $54.4 milli
Read more →AIMAIM ImmunoTech CEO Thomas K. Equels Participates in Fireside Chat with Ascendiant Capital Markets Analyst Ed Woo
OCALA, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces that Thomas K. Equels, CEO of AIM ImmunoTech, participated in a ‘Fireside Chat’ video interview with Ed Woo, Director of Research & Senior Analyst at Ascendiant Capital Markets. Duri
Read more →AIMAIM ImmunoTech Announces Positive Safety Data in Second Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID-19 and Other Respiratory Viral Diseases
OCALA, Fla., April 27, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 2 in a Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as an intranasal therapy, reporting
Read more →AIMAIM ImmunoTech Announces Positive Safety Data in First Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID-19 and Other Respiratory Viral Diseases
OCALA, Fla., April 07, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of AIM’s drug Ampligen as an intranasal therapy, reporting no serious adverse events, and pa
Read more →AIMAIM ImmunoTech Reports 2020 Year-End Financial Results
OCALA, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the fiscal year ended December 31, 2020 and provides a business update. 2020 Financial Highlights As of December 31, 2020, AIM had cash, cash equivalents and
Read more →AIMAIM ImmunoTech Announces Addition of Single-Agent Ampligen Arm to Cancer Center’s Ongoing Study in Cancer Patients with COVID-19
OCALA, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that the Institutional Review Board (IRB) of Roswell Park Comprehensive Cancer Center (Roswell Park) has approved a protocol amendment to Roswell Park’s ongoing Phase 1/2a stu
Read more →AIMAIM ImmunoTech to Present at the Q1 Virtual Investor Summit on March 24th
OCALA, Fla., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, will be presenting at the Q1 Virtual Investor Summit. Event Q1 Investor Summit Date March
Read more →AIMAIM ImmunoTech to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
OCALA, Fla., March 10, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, AIM’s Chief Executive Officer, has been invited to present at the Inaugural Emerging Growth Virtual Conference, presented by M Vest LLC and Maxim Group
Read more →AIMAIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical Study
OCALA, Fla., March 08, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has dosed the first healthy subjects in its Phase 1 clinical study on the safety of AIM’s drug Ampligen as a potential intranasal therapy. AIM’s ’s goal is to develop
Read more →AIMAIM ImmunoTech to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th
OCALA, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, will be presenting at the H.C. Wainwright Life Sciences Conference to be held virtually between March 9-10, 2
Read more →AIMAIM ImmunoTech’s Subsidiary Receives Orphan Medicinal Product Designation by the European Medicines Agency for Ampligen to Treat Pancreatic Cancer
OCALA, Fla., Feb. 24, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that its subsidiary, NV Hemispherx Biopharma Europe, has received formal notification from the European Commission (EC) approving the company’s Orphan Medicinal Product Applica
Read more →AIM(Unofficial Translation) EUROPEAN COMMITTEE Brussels, 19FEB2021 C(2021) 1285 final IMPLEMENTATION DECISION OF THE COMMITTEE of 19FEB2021 on the designation of the "Rintatolimod" medicinal product as an orphan medicinal p
DECISION OF THE COMMITTEE the designation of the "Rintatolimod" medicinal product as an orphan medicinal product under (EC) Regulation No 141/2000 of the European Parliament and of the Council relevant to the EEA) TEXT IN THE DUTCH LANGUAGE SHALL BE CONSIDERED AS AUTHENTIC)
Read more →AIMAIM ImmunoTech Announces Ethics Committee Approval to Commence Phase 1 Clinical Study of Ampligen as an Intranasal Therapy
OCALA, Fla., Feb. 16, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has received approval from the required Ethics Committee in the Netherlands to commence its Phase 1 clinical study on the safety of AIM’s drug Ampligen as an intranasal
Read more →AIMAIM ImmunoTech Announces the Expansion of its Pancreatic Cancer Program to Include New Patients in the Netherlands
OCALA, Fla., Feb. 10, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that the Dutch Health and Youth Care Inspectorate (IGJ) has approved treatment for six pancreatic cancer patients as part of a new, follow-up Early Access Program (EAP) at Eras
Read more →AIMAIM ImmunoTech Completes and Closes ATM Facility; Current Capital Expected to Meet Needs for Current Clinical Trials
OCALA, Fla., Feb. 05, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed its At-The-Market (ATM) facility and closed the ATM’s Equity Distribution Agreement (EDA). Management believes, based on the company’s current financial c
Read more →AIMAIM ImmunoTech Enters into Agreement for Proposed Intranasal Safety Study of Ampligen
OCALA, Fla., Jan. 29, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has entered into a sponsorship agreement with the Centre for Human Drug Research (CHDR) for the proposed AMP-COV-100 (CHDR2049) clinical study on the safety of AIM’s dr
Read more →AIMAIM ImmunoTech Reschedules Investor Conference Call to January 21, 2021 at 11AM ET
OCALA, Fla., Jan. 15, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has rescheduled its investor conference call for 11:00 a.m. Eastern Time on Thursday, January 21, 2021 to discuss the recently announced commencement of the treatment o
Read more →AIMAIM ImmunoTech Postpones Investor Conference Call. Will Reschedule for a Later Date
OCALA, Fla., Jan. 11, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) and its CEO Thomas K. Equels today announced that this week’s planned investor conference call will be postponed and rescheduled for a later date following the death of Mr. Equels’ mother over
Read more →AIMAIM ImmunoTech Announces First COVID-19-Induced Chronic Fatigue “Long Hauler” Patient Dosed with Ampligen
OCALA, Fla., Jan. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that the active AMP-511 Expanded Access Program (EAP) has dosed its first COVID-19 “Long Hauler” patient with the drug Ampligen (rintatolimod), marking a significant milestone
Read more →AIMAIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 ‘Long Haulers’
OCALA, Fla., Dec. 24, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announced today that the post-COVID-19 “Long Hauler” portion of the active AMP-511 Expanded Access Program (EAP) protocol received approval from the Institutional Review Board (IRB) for a publ
Read more →AIMAIM ImmunoTech Inc.’s Drug Ampligen Awarded FDA’s Orphan Drug Designation Status for the Treatment of Pancreatic Cancer
OCALA, Fla., Dec. 21, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today announced that the U.S. Food an
Read more →AIMAIM ImmunoTech Provides Third Quarter 2020 Business Update
OCALA, Fla., Nov. 13, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today provided a business update for
Read more →AIMAIM ImmunoTech Announces PLOS ONE’s Publication of New Data Analyses Showing Importance of Disease Duration on Ampligen’s Positive Role in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
OCALA, Fla., Nov. 02, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announced today the publication of statistically significant data detailing how its drug Ampligen could have a considerable positive impact on people living with the debilitating illness myalg
Read more →AIMAIM ImmunoTech CEO to Participate in Virtual Panel Presentation at the 23rd Annual BioFlorida Conference on October 29th
OCALA, Fla. , Oct. 22, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, is scheduled to participate in a virtual panel titled, “COVID-19: Progress on Treatments & Prevention” on Thu
Read more →AIMAIM ImmunoTech Announces IRB Approval to Enroll COVID-19 ‘Long Haulers’ in the AMP-511 ME/CFS Clinical Trial of Ampligen
OCALA, Fla., Oct. 06, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) is pleased to announce that it has received Institutional Review Board (IRB) approval for the expansion of the AMP-511 Expanded Access Program (EAP) clinical trial for Myalgic Encephalomyeliti
Read more →AIMclinical trials. AMED is funding at least five research projects related to COVID-19. Aside from the vaccine effort, it's supporting basic science for coronavirus rapid- diagnosis kits and therapeutic drugs to treat pati
trials. AMED is funding at least five research projects related to COVID-19. Aside from the vaccine effort, it's supporting basic science for coronavirus rapid- diagnosis kits and therapeutic drugs to treat patients with COVID-19, and exploring the use of animal models such as
Read more →AIMAIM ImmunoTech Signs Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center Supporting Phase 1/2 Clinical Trial of Ampligen Combined with Interferon Alfa-2b in COVID-19 Patients with Cancer Agreement Impo
ImmunoTech Signs Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center Supporting Phase 1/2 Clinical Trial of Ampligen Combined with Interferon Alfa-2b in COVID-19 Patients with Cancer Important Precursor to Next Step, Enrollment is a Study Collaborator and Fi
Read more →AIMAIM ImmunoTech Signs Material Transfer and Research Agreement with Japan's National Institute of Infectious Diseases and Shionogi, a Leading Global Pharmaceutical Company, to Test Ampligen as Potential Vaccine Adjuvant f
ImmunoTech Signs Material Transfer and Research Agreement with Japan's National of Infectious Diseases and Shionogi, a Leading Global Pharmaceutical Company, Test Ampligen as Potential Vaccine Adjuvant for COVID-19 Fla. - July 6, 2020 - AIM ImmunoTech (NYSE American: AIM), tod
Read more →AIMAIM ImmunoTech Provides Update on Commercial Launch of Ampligen in Argentina for the Treatment of Chronic Fatigue Syndrome Receives clearance from Argentina's FDA to import first shipment of Ampligen for commercial sale
ImmunoTech Provides Update on Commercial Launch of Ampligen in Argentina for the Treatment of Chronic Fatigue clearance from Argentina's FDA to import first shipment of Ampligen for commercial sale in Argentina 'sets sights' on treating COVID-19 induced chronic fatigue in Argen
Read more →AIMAIM ImmunoTech and Shenzhen Smoore Technology Announce an Agreement to Research Utilizing an Innovative Smoore Inhalation Delivery Device and Ampligen (rintatolimod) as a Potential, Easy-To-Use Treatment Approach for the
ImmunoTech and Shenzhen Smoore Technology Announce an Agreement to Research Utilizing an Innovative Smoore Inhalation Delivery Device and Ampligen (rintatolimod) as a Potential, Easy-To-Use Treatment Approach for the SARS-CoV-2 Pandemic Fla. - April 6, 2020 - AIM ImmunoTech (NY
Read more →AIMAIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic
ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic Fla. - March 26, 2020 - AIM ImmunoTech (NYSE American: AIM) today announced that it is actively seeking in
Read more →AIMAIM ImmunoTech's Drug Ampligen to Be Tested by Japan's National Institute of Infectious Diseases as a Potential Treatment for the New SARS Coronavirus (SARS-CoV-2) Responsible for the New Human Infectious Disease COVID-1
ImmunoTech's Drug Ampligen to Be Tested by Japan's National Institute of Infectious Diseases as a Potential Treatment for the New SARS Coronavirus (SARS-CoV-2) Responsible for the New Human Infectious Disease COVID-19 Fla. - March 9, 2020 - AIM ImmunoTech (NYSE American: AIM),
Read more →AIMAIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen for Use Against the SARS-like Wuhan 2019 Novel Coronavirus
Ampligen® obtained 100% survival rate at clinically achievable human dosage levels for SARS in animal experiments Ampligen key to proposed broad-spectrum ‘universal’ coronavirus vaccine OCALA, Fla., Feb. 11, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) toda
Read more →AIMAIM ImmunoTech Issues Stockholder Update and Details Its Expectations for 2020
ImmunoTech Issues Stockholder Update and Details Its Expectations for 2020 Fla., December 4, 2019 - AIM ImmunoTech (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency dise
Read more →AIMAIM ImmunoTech Provides Comprehensive Clinical Trials Update With Major Inflection Points Identified Well Capitalized to Complete Current Ampligen Clinical Trials Following $10M in Capital Raises Plus $15M Recently Award
ImmunoTech Provides Comprehensive Clinical Trials Update With Major Inflection Points Identified Capitalized to Complete Current Ampligen Clinical Trials Following $10M in Capital Raises Plus $15M Recently Awarded by DOD to Roswell Park and Moffitt for Ampligen-Related Breast C
Read more →AIMAIM ImmunoTech, Inc. Announces Pricing of $8 Million Public Offering OCALA, FL (
ImmunoTech, Inc. Announces Pricing of $8 Million Public Offering FL (September 25, 2019) - AIM ImmunoTech, Inc. (NYSE American: AIM) (the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, today annou
Read more →AIMAIM ImmunoTech Inc. Announces a Second DoD Award, This One of $8.3 Million, to Fund Phase 2 Clinical Trial to Study Ampligen as Part of a New Treatment for Brain-Metastatic Breast Cancer at the Moffitt Cancer Center New
ImmunoTech Inc. Announces a Second DoD Award, This One of $8.3 Million, to Fund Phase 2 Clinical Trial to Study Ampligen as Part of a New Treatment for Brain-Metastatic Breast Cancer at the Moffitt Cancer Center Ampligen-Related Strategy for Treating Advanced Breast Cancer Help
Read more →AIMAIM ImmunoTech Names Ellen Lintal as New Chief Financial Officer
ImmunoTech Names Ellen Lintal as New Chief Financial Officer Fla., September 16, 2019 - AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases -
Read more →AIMHemispherx Biopharma, Inc. Changes Name to AIM ImmunoTech Inc. Reflecting Ampligen's Immuno Modulation Progress in Ongoing Oncology Clinical Trials and ME/CFS Announces new ticker symbol AIM' effective
Biopharma, Inc. Changes Name to AIM ImmunoTech Inc. Reflecting Ampligen's Immuno Modulation Progress in Ongoing Oncology Clinical Trials and ME/CFS new ticker symbol AIM' effective September 3, 2019 Fla., Aug. 23, 2019 - Hemispherx Biopharma, Inc. (NYSE American: HEB), an immu
Read more →AIMHemispherx Biopharma CFO Adam Pascale Announces Retirement OCALA, Fla. (
Biopharma CFO Adam Pascale Announces Retirement Fla. (June 28, 2019) - Hemispherx Biopharma, Inc. (NYSE American: HEB) announced today that Adam Pascale is retiring from the position of Chief Financial Officer after nearly a quarter century with the company. joined Hemispherx
Read more →AIMHemispherx Biopharma Stockholders Approve Reverse Stock Split OCALA, Fla. (
Biopharma Stockholders Approve Reverse Stock Split Fla. (May 31, 2019) - Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, today an
Read more →AIMHemispherx Biopharma Updates the Terms of Previously Announced Rights Offering and Announces Senior Management and Directors All Plan to Participate in the Offering OCALA, Fla. (
Biopharma Updates the Terms of Previously Announced Rights Offering and Announces Senior Management and Directors All Plan to Participate in the Offering Fla. (February 27, 2019) - Hemispherx Biopharma, Inc. (NYSE American: HEB) ("Hemispherx" or the "Company"), an immuno-pharm
Read more →AIMHemispherx Biopharma Announces Commencement of a New 45 Subject Clinical Trial Combining Ampligen and Merck's Keytruda in the Treatment of Recurrent Ovarian Cancer
Biopharma Announces Commencement of a New 45 Subject Clinical Trial Combining Ampligen and Merck's Keytruda in the Treatment of Recurrent Ovarian Cancer Fla., February 11, 2019 - Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on unmet medical
Read more →AIMHemispherx Biopharma Announces Key Dates and Timeline for Stockholder Participation in Rights Offering OCALA, Fla. (
Biopharma Announces Key Dates and Timeline for Stockholder Participation in Rights Offering Fla. (February 6, 2019) - Hemispherx Biopharma, Inc. (NYSE American: HEB) ("Hemispherx" or the "Company"), an immuno-pharma R&D and emerging commercial growth company focused on unmet me
Read more →AIMHemispherx Outlines Ampligen Combination Therapy Clinical Study Strategy for the Treatment of Multiple Cancers in Letter to Stockholders ORLANDO, Fla. (
Outlines Ampligen Combination Therapy Clinical Study Strategy for the Treatment of Multiple Cancers in Letter to Stockholders Fla. (October 22, 2018) - Hemispherx Biopharma, Inc. (NYSE American: HEB) announces that Thomas K. Equels, President and Chief Executive Officer, has is
Read more →AIMHemispherx Biopharma Signs Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center to Study Ampligen in Combination with Checkpoint Inhibitors in a Phase IIa Study in Urothelial Carcinoma, Renal Cell Carci
Biopharma Signs Clinical Trial Agreement with Park Comprehensive Cancer Center to Study Ampligen in Combination with Inhibitors in a Phase IIa Study in Urothelial Carcinoma, Renal Cell Carcinoma and Melanoma Agreement Expands Existing Preclinical Collaborations Fla. (October
Read more →AIMDear Fellow Stockholders: As you probably know, we recently announced the completion of fill and finish operations for our first commercial-size lot of Ampligen at our Contract Manufacturing Organization ("CMO"). More th
Fellow Stockholders: you probably know, we recently announced the completion of fill and finish operations for our first commercial-size lot of Ampligen at our Contract Manufacturing Organization ("CMO"). More than 8,500 vials now await routine release testing before heading t
Read more →AIMHemispherx Announces Pricing of $2.57 Million Registered Direct Offering at a Premium to Market
Hemispherx Announces Pricing of $2.57 Million Registered Direct Offering at a Premium to Market ORLANDO, Fla., April 20, 2018 (GLOBE NEWSWIRE) - Hemispherx Biopharma, Inc.(NYSE American: HEB) ("Hemispherx" or the "Company"), a research and development and emerging commercial
Read more →AIMCompany/Investor Contact: Charles Jones CJones & Associates Public Relations 888-557-6480 305-987-7418 cjones@cjonespr.com Hemispherx Biopharma Announces Corporate Progress and Financial Results for the Six Months Ended
& Associates Public Relations Biopharma Announces Corporate Progress and Financial Results for the Six Months Ended June 30, 2017 Company has Generated Revenues and Advanced in R&D for Intranasal Ampligen and in Immuno-Oncology Call Scheduled for Tuesday, August 15th at 1:00
Read more →AIMCompany/Investor Contact: Charles Jones CJones & Associates Public Relations 888-557-6480 305-987-7418 cjones@cjonespr.com Hemispherx Biopharma Announced Financial Results for the Year Ended December 31, Hemispherx Bioph
& Associates Public Relations Biopharma Announced Financial Results for the Year Ended December 31, Biopharma Management Team Continues Its Aggressive Commitment to Strategies Designed to Reach Commercial Goals, Preserve Financial Capital, and Increase Stockholder Value Call
Read more →AIMCompany/Investor Contact: Charles Jones CJones & Associates Public Relations 888-557-6480 cjones@cjonespr.com Hemispherx Biopharma, Inc. Announces $1 Million Registered Direct Offering PHILADELPHIA, FEBRUARY 2, 2017 - He
Company/Investor Contact: CJones & Associates Public Relations Hemispherx Biopharma, Inc. Announces $1 Million Registered Direct Offering PHILADELPHIA, FEBRUARY 2, 2017 - Hemispherx Biopharma, Inc. (NYSE MKT: HEB) (the "Company" or "Hemispherx"), announced today that it has
Read more →AIMCompany/Investor Contact: Charles Jones CJones & Associates Public Relations 888-557-6480 305-987-7418 cjones@cjonespr.com Hemispherx Biopharma Announces Financial Results in its Quarterly Report for the Nine Months Ende
Company/Investor Contact: CJones & Associates Public Relations Biopharma Announces Financial Results in its Quarterly Report for the Nine Months Ended September 30, 2016 Call Scheduled for Tuesday, November 15, 2016 at 11:00 AM EST - November 14, 2016 - Hemispherx Biopharma
Read more →AIMCompany/Investor Contact: Charles Jones CJones & Associates Public Relations 888-557-6480 305-987-7418 cjones@cjonespr.com Hemispherx Biopharma Announces Granting of Final Settlement of Derivative and Class Action Case P
Company/Investor Contact: CJones & Associates Public Relations Hemispherx Biopharma Announces Granting of Final Settlement of Derivative and Class Action Case PHILADELPHIA - September 22, 2016 - Hemispherx Biopharma (NYSE MKT: HEB) (the "Company"), announced today that the C
Read more →AIMCompany/Investor Contact: Charles Jones CJones & Associates Public Relations 888-557-6480 305-987-7418 cjones@cjonespr.com Hemispherx Biopharma Regains Compliance with NYSE MKT Continued Listing Standards PHILADELPHIA
& Associates Public Relations Biopharma Regains Compliance with NYSE MKT Continued Listing Standards - September 19, 2016 - Hemispherx Biopharma (NYSE MKT: HEB) (the "Company"), announced today that, based on a notice received on September 15, 2016 from the New York Stock Exch
Read more →AIMCompany/Investor Contact: Charles Jones CJones & Associates Public Relations 888-557-6480 cjones@cjonespr.com Hemispherx Biopharma, Inc. Announces $5 Million Registered Direct Offering PHILADELPHIA, AUGUST 31, 2016 -- He
Company/Investor Contact: CJones & Associates Public Relations Biopharma, Inc. Announces $5 Million Registered Direct Offering PHILADELPHIA, AUGUST 31, 2016 -- Hemispherx Biopharma, Inc. (NYSE MKT: HEB) (the "Company" or "Hemispherx"), announced today that it has entered int
Read more →AIMCom pany/Investor Contact Charles Jones CJones & Associates Public Relations Office: 888-557-6480 Cell: 305-987-7418 Email: cjones@cjonespr.com Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial S
Company/Investor Contact CJones & Associates Public Relations Office: 888-557-6480 Email: cjones@cjonespr.com Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen ) to Treat Severe Cases of Myalgic Encepha
Read more →AIMCompany/Investor Contact Charles Jones CJones & Associates Public Relations Office: 888-557-6480 Cell: 305-987-7418 Email: cjones@cjonespr.com Hemispherx Biopharma Forms Scientific Advisory Board to Provide Additional Sc
CJones & Associates Public Relations Office: 888-557-6480 Email: cjones@cjonespr.com Biopharma Forms Scientific Advisory Board to Provide Additional Scientific and Pharmaceutical Expertise August 19, 2016 - Hemispherx Biopharma (NYSE MKT: HEB) announced that it has formed a s
Read more →AIMCompany/Investor Contact: Charles Jones CJones & Associates Public Relations 888-557-6480 305-987-7418 cjones@cjonespr.com Hemispherx Biopharma Announces 1-for-12 Reverse Stock Split PHILADELPHIA
Company/Investor Contact: CJones & Associates Public Relations Hemispherx Biopharma Announces 1-for-12 PHILADELPHIA - August 17, 2016 - Hemispherx Biopharma (NYSE MKT: HEB) (the "Company), announced today that it will effect a 1-for-12 reverse stock split of its common stock
Read more →AIMCompany/Investor Contact: Charles Jones CJones & Associates Public Relations 888-557-6480 305-987-7418 cjones@cjonespr.com Hemispherx Biopharma Announces Financial Results for the Six Months Ended
Company/Investor Contact: CJones & Associates Public Relations Hemispherx Biopharma Announces Financial Results for the Six Months Ended June 30, 2016 The company continues to focus on commercial success by seeking co-development partners and working closely with the researc
Read more →AIMCompany/Investor Contact Charles Jones CJones & Associates Public Relations Office: 888-557-6480 Cell: 305-987-7418 Email: cjones@cjonespr.com Hemispherx Updates the Status of the Alferon Manufacturing Facility PHILADELP
Company/Investor Contact CJones & Associates Public Relations Office: 888-557-6480 Email: cjones@cjonespr.com Hemispherx Updates the Status of the Alferon Manufacturing Facility PHILADELPHIA - July 11, 2016 - Hemispherx Biopharma (NYSE MKT: HEB) in response to various ques
Read more →AIMUNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA MARK ZICHERMAN, Derivatively on ) Case No. 2:13-cv-00243 Behalf of HEMISPHERX ) BIOPHARMA, INC., ) ) Hon. Wendy Beetlestone Plaintiff, ) vs. ) ) WILLIAM A. CA
UNITED STATES DISTRICT EASTERN DISTRICT OF PENNSYLVANIA MARK ZICHERMAN, Derivatively on ) Case No. 2:13-cv-00243 Behalf of HEMISPHERX ) BIOPHARMA, INC., ) ) Hon. Wendy Beetlestone Plaintiff, ) vs. ) ) WILLIAM A. CARTER, et al. , ) ) Defendants, ) ) - and
Read more →AIMCompany/Investor Contact: Charles Jones CJones & Associates Public Relations Office: 888-557-6480 Cell: 305-987-7418 Email: cjones@cjonespr.com Hemispherx Biopharma Enters into Settlement Agreements Dismissing All Pendin
Company/Investor Contact: CJones & Associates Public Relations Office: 888-557-6480 Email: cjones@cjonespr.com Hemispherx Biopharma Enters into Settlement Agreements Dismissing All Pending Shareholder Derivative Litigation, Resolving Disputes with Insurance Carriers, and Obt
Read more →AIMCompany/Investor Contact: Charles Jones CJones & Associates Public Relations 888-557-6480 305-987-7418 cjones@cjonespr.com Hemispherx Amends and Restates Agreement with myTomorrows for the Early Access Program for Rintat
& Associates Public Relations Amends and Restates Agreement with myTomorrows for the Early Access Program for Rintatolimod in Europe - May 24, 2016 - Hemispherx Biopharma (NYSE MKT: HEB) announced today that it has executed an amended and restated agreement with Impatients, N.
Read more →AIMCompany/Investor Contact: Charles Jones CJones & Associates Public Relations 888-557-6480 305-987-7418 cjones@cjonespr.com HEMISPHERX BIOPHARMA ANNOUNCES FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2015 Hemispherx
& Associates Public Relations BIOPHARMA ANNOUNCES FINANCIAL RESULTS THE YEAR ENDED DECEMBER 31, 2015 Biopharma Management Team: Reflects Company's Aggressive Commitment to Strategies Designed to Reach Commercial Goals, Preserve Financial Capital, and Increase Stockholder Valu
Read more →AIMCompany/Investor Contact Charles Jones CJones & Associates Public Relations Office: 888-557-6480 Cell: 305-987-7418 Email: cjones@cjonespr.com Hemispherx Biopharma Management Team: Reflects Company's Aggressive Commitmen
Company/Investor Contact CJones & Associates Public Relations Office: 888-557-6480 Email: cjones@cjonespr.com Hemispherx Biopharma Management Team: Reflects Company's Aggressive Commitment to Strategies Designed to Reach Commercial Goals, Preserve Financial Capital, and Inc
Read more →AIMCompany/Investor Contact: Charles Jones CJones & Associates Public Relations Office: 888-557-6480 Cell: 305-987-7418 Email: cjones@cjonespr.com Hemispherx Biopharma Introduces a Voluntary Stock Purchase Plan to Create Sh
Company/Investor Contact: CJones & Associates Public Relations Office: 888-557-6480 Email: cjones@cjonespr.com Hemispherx Biopharma Introduces a Voluntary Stock Purchase Plan to Create Shareholder Value Senior Management, Entire Board of Directors, and 100% of All Employee
Read more →AIMHemispherx Receives New U.S. Composition of Matter Patent Covering Ampligen Formulations Novel Molecular Composition Provides Patent Protection for Current and Future Ampligen Formulations to at Least 2029 PHILADELPHIA
Hemispherx Receives New U.S. Composition of Matter Patent Covering Ampligen Formulations Novel Molecular Composition Provides Patent Protection for Current and Future Ampligen Formulations to at Least 2029 PHILADELPHIA - May 27, 2014: Hemispherx Biopharma, Inc. (NYSE MKT: HEB)
Read more →AIMCompany/Investor Contact: Dianne Will Hemispherx Biopharma, Inc. 518-398-6222 ir@hemispherx.net Hemispherx Biopharma Appoints New Chief Financial and Chief Accounting Officers ..Seasoned Executives in Financial and Accou
Company/Investor Contact: Hemispherx Biopharma, Inc. Hemispherx Biopharma Appoints New Chief Financial and Chief Accounting Officers ..Seasoned Executives in Financial and Accounting Matters with International Experience Philadelphia, PA, December 4, 2013: Hemispherx Biopharm
Read more →AIMCompany/Investor Contact: Dianne Will Hemispherx Biopharma, Inc. 518-398-6222 ir@hemispherx.net Hemispherx Biopharma's 2013 Stockholder Annual Meeting Proposal 4 Removed From Stockholder Consideration Philadelphia, PA
Company/Investor Contact: Hemispherx Biopharma, Inc. Hemispherx Biopharma's 2013 Stockholder Annual Meeting Proposal 4 Removed From Stockholder Consideration Philadelphia, PA - October 3, 2013: Hemispherx Biopharma, Inc. (NYSE MKT: HEB) (the "Company") announced that its Boar
Read more →AIMCompany/Investor Contact: Dianne Will Hemispherx Biopharma, Inc. 518-398-6222 ir@hemispherx.net Hemispherx Biopharma Appoints Peter W. Rodino III, Esq. to the Board of Directors and to Serve as Chairman of the Company's
Company/Investor Contact: Hemispherx Biopharma, Inc. Hemispherx Biopharma Appoints Peter W. Rodino III, Esq. to the Board of Directors and to Serve as Chairman of the Company's Audit Committee Philadelphia, PA, July 29, 2013: Hemispherx Biopharma, Inc. (NYSE MKT: HEB) (the "Co
Read more →AIMCompany/Investor Contact: Dianne Will Hemispherx Biopharma, Inc. 518-398-6222 ir@hemispherx.net Hemispherx Biopharma Receives Complete Response Letter from FDA on Ampligen New Drug Application for Chronic Fatigue Syndrom
Company/Investor Contact: Hemispherx Biopharma, Inc. Hemispherx Biopharma Receives Complete Response Letter from FDA on Ampligen New Drug Application for Chronic Fatigue Syndrome Hemispherx will seek an End-of-Review Conference with the FDA Philadelphia, PA - February 4,
Read more →AIMCompany/Investor Contact: Dianne Will Hemispherx Biopharma, Inc. 518-398-6222 ir@hemispherx.net FDA Advisory Committee Makes Recommendations on Ampligen for Chronic Fatigue Syndrome Philadelphia, PA
Company/Investor Contact: Hemispherx Biopharma, Inc. FDA Advisory Committee Makes Recommendations on Ampligen for Chronic Fatigue Syndrome Philadelphia, PA, December 21, 2012: Hemispherx Biopharma, Inc. (NYSE MKT: HEB) (the "Company" or "Hemispherx") today announced the outc
Read more →Competitive Position
How AIM ranks across every disease it competes inCompetitive Position is a premium feature
See how AIM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial